Lipidoid compositions and methods of use thereof

JP2023552555A5Pending Publication Date: 2024-12-06TRUSTEES OF TUFTS COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534118
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-07
Filing Date
2021-12-07
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current cancer vaccines face challenges due to tumor-associated antigen variability and immunosuppressive tumor microenvironments, leading to low efficacy and severe side effects from excessive immune activation, such as cytokine release syndrome.

Method used

Development of lipidoid compositions, including nanoparticles (LNPs) that enhance cross-presentation of tumor antigens and activate the STING pathway by delivering cGAMP, combined with doxorubicin to induce immunogenic cancer cell death and antigen release.

Benefits of technology

The lipidoid compositions effectively promote anti-tumor immune responses, achieving complete recovery in 35% of mice from primary tumors and 71% from subsequent challenges, with improved safety and efficacy compared to existing in situ vaccination methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022125589000001
    Figure 2022125589000001
  • Figure 2022125589000002
    Figure 2022125589000002
  • Figure 2022125589000003
    Figure 2022125589000003
Patent Text Reader

Abstract

Lipidoid compositions are disclosed that can treat or prevent certain diseases (e.g., cancer or viral infections). Pharmaceutical compositions containing the lipidoid compositions are also disclosed. Methods of using the lipidoid compositions and related kits containing the lipidoid compositions are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

Cross-reference of related applications

[0001] This application claims priority to U.S. Provisional Application No. 63 / 122,229, filed on 7 December 2020; its contents are incorporated herein in full by reference. Government support

[0002] This invention was made with government support under grant number R01 EB027170-01 granted by the National Institutes of Health (NIH). The government has certain rights to this invention. [Background technology]

[0003] Cancer vaccines have been under development for decades, offering a new option for treating cancer. While this approach shows considerable promise for eradicating cancer, only one cell-based vaccine has been approved by the U.S. Food and Drug Administration (FDA) to date, and overall clinical efficacy remains low. Two major obstacles have hindered the development of cancer vaccines: the large variability of tumor-associated antigens (TAAs) across different tumors and even between different patients with the same tumor, and the immunosuppressive tumor microenvironment. Personalized vaccines based on neoantigens and immune checkpoint inhibitors have been developed to overcome these challenges, but these methods are complex, expensive, and have only been effective in small populations. In situ vaccination is considered a promising alternative strategy to cancer vaccination, as it does not require the identification and isolation of TAAs. By topical administration of therapeutic or immunomodulatory agents, in situ vaccination aims to leverage abundant TAAs and activate the immunosuppressive tumor microenvironment, thus offering the potential for broad application.

[0004] The use of oncolytic viruses is the most common method of in situ vaccination and has been studied in clinical trials for metastatic melanoma. However, the excessive activation of the immune system by oncolytic viruses is a major concern for its application in humans, as it can lead to serious side effects such as cytokine release syndrome (CRS). To date, several other in situ vaccination strategies, including photothermal therapy (PTT), radiotherapy (RT), agonist immunotherapy, and even chemotherapy, have also been shown to induce effective immune responses. However, PTT, RT, and chemotherapy are only superior in the production of tumor antigens by inducing immunogenic cell death, and the delivery and presentation of these released antigens remains limited by immune tolerance in the tumor microenvironment. In situ application of immune agonists can boost the immune response but lacks the production of tumor antigens. To evoke an effective antitumor immune response, an in situ vaccine should ideally be able to induce immunogenic cancer cell death, promote TAA release, enhance antigen presentation, and stimulate the activation of the antitumor T cell response.

[0005] Based on the above, there is still an unmet need for new vaccines. [Overview of the Initiative] [Means for solving the problem]

[0006] In situ vaccination is a promising strategy for cancer immunotherapy due to its convenience and ability to induce a large number of tumor antigens. However, advances in in situ vaccination techniques are hindered by the low cross-presentation of tumor antigens and the immunosuppressive tumor microenvironment. To balance the safety and efficacy of in situ vaccination, a lipidoid composition, such as nanoparticles (LNPs), was designed to simultaneously enhance cross-presentation and STING activation. From screening a library of LNPs, 93-O17S-F was identified. 93-O17S-F promotes both the cross-presentation of tumor antigens and the intracellular delivery of cGAMP (a STING agonist). Intratumoral injection of 93-O17S-F / cGAMP combined with doxorubicin pretreatment showed excellent antitumor efficacy, with 35% of mice showing total recovery from primary B16F10 tumors and 71% showing complete recovery from subsequent challenges, indicating the induction of immunological memory against the tumor. Therefore, the disclosure herein provides promising strategies for in situ cancer immunotherapy.

[0007] In one embodiment, the present disclosure provides a lipidoid composition (e.g., nanoparticles) comprising a plurality of lipidoids and an adjuvant (e.g., an immunomodulator), an antigen, or a nucleic acid.

[0008] In another aspect, the Disclosure provides a pharmaceutical composition comprising a lipidoid composition disclosed herein.

[0009] In another aspect, the Disclosure provides a method for treating or preventing a disease or disorder in a target area of ​​interest using the lipidoid compositions disclosed herein.

[0010] In another aspect, the Disclosure provides a method for treating cancer in a target subject using the lipidoid compositions disclosed herein.

[0011] In another aspect, the Disclosure provides a method for treating or preventing viral infections in a target area using the lipidoid compositions disclosed herein.

[0012] In another embodiment, the present disclosure provides a kit comprising the lipidoid composition disclosed herein. [Brief explanation of the drawing]

[0013] [Figure 1] The mechanism of LNP system-mediated cross-presentation and STING activation is demonstrated. (I) Low doses of DOX induced immunogenic cancer cell death. (II) Tumor antigens were released after administration of low doses of DOX. (III) The released antigens were captured by LNP / cGAMP. (IV) The tumor antigens and cGAMP were delivered to APC cells via endocytosis. (V) The tumor antigens and cGAMP escaped from endo / lysosomes for further cross-presentation and STING activation. [Figure 2A] Figures 2A–2G show the adjuvant effect and enhanced cross-presentation of LNPs. Figure 2A shows the procedure for screening an LNP library using the prime-boost procedure. [Figure 2B] The antibody titer of OVA-specific IgG after immunization using OVA-containing LNPs is shown (n=3). [Figure 2C] The antibody titer of OVA-specific IgG1 after immunization using OVA-containing LNPs is shown (n=3). [Figure 2D] The antibody titer of OVA-specific IgG2c after immunization using OVA-equipped LNPs is shown (n=3). [Figure 2E] This indicates that enhanced antigen delivery by LNPs upregulated cross-presentation. [Figure 2F] Typical flow cytometry data of SIINFEKL-MHC I complex expression in DC2.4 cells after incubation with different OVA formulations are shown. [Figure 2G]The mean fluorescence intensity (MFI) of the labeled SIINFEKL-MHC I complex, calculated by flow cytometry, is shown (n=4). [Figure 3A] Figures 3A to 3E show the enhancement of STING activation by cytoplasmic delivery of cGAMP in vitro. Figure 3A shows the activation of the STING pathway by cytoplasmic delivery of cGAMP using 93-017S-F. [Figure 3B] This shows the intracellular distribution of cGAMPFluo and lysosomes in RAW264.7 and DC2.4 cells after 4 hours of incubation with free cGAMPFluo or 93-O17S-F / cGAMPFluo. [Figure 3C] This shows the relative expression of the ifnb1 gene in RAW264.7 and DC2.4 cells after 4 hours of incubation with 93-O17S-F / cGAMP. [Figure 3D] This shows the relative expression of the cxcl10 gene in RAW264.7 and DC2.4 cells after 4 hours of incubation with 93-O17S-F / cGAMP. [Figure 3E] The concentrations of IFN-β in the culture medium of DC2.4 cells after incubation with 93-O17S / cGAMP for 4 hours and 24 hours are shown. [Figure 4A] Figures 4A to 4I show that LNP enhances STING activation in vivo and shifts the immune cell composition of the tumor microenvironment. Figure 4A shows the capture of tumor antigens by 93-O17S-F. [Figure 4B] The diameter and zeta potential of the 93-017S-F and tumor lysate complex at different weight ratios are shown. [Figure 4C] This shows enhanced delivery of OVAAlexa647 to draining lymph nodes after capture by 93-O17S-F in vivo. [Figure 4D] This document outlines the procedure for in vivo STING activation experiments. [Figure 4E]This shows the relative expression of the ifnb1 gene in B16F10 tumors 6 hours after administration of 93-O17S-F / cGAMP (n=6, *:P≦0.05). [Figure 4F] This shows the relative expression of the cxcl10 gene in B16F10 tumors 6 hours after administration of 93-O17S-F / cGAMP (n=6, *:P≦0.05). [Figure 4G] This shows activation of the STING pathway, which recruits immune cells to the tumor site. [Figure 4H] The cell counts of CD4+ and CD8+ T cells in tumor sites 48 hours after administration of 93-O17S-F / cGAMP are shown. n=5, *:P≦0.05, ***:P≦0.01. [Figure 4I] This shows the number of DCs and macrophages in the tumor site 48 hours after administration of 93-O17S-F / cGAMP. n=5, *:P≦0.05. [Figure 5A] Figures 5A-5G show the antitumor therapeutic effect of 93-O17S-F / cGAMP. Figure 5A shows the procedure for in situ vaccination with 93-O17S / cGAMP. [Figure 5B] The image shows a photograph of the B16F10 xenograft tumor on day 6. [Figure 5C] The tumor volume of B16F10 xenograft tumors after treatment with different formulations is shown (n=6, ***: p≦0.001). [Figure 5D] This shows the individual tumor volumes after treatment with different formulations. [Figure 5E] This shows the survival rate of mice with B16F10 xenograft tumors. [Figure 5F] The procedure for the tumor rechallenge assay is shown below. [Figure 5G] This shows the percentage of total recovery in mice inoculated with primary tumors and mice in re-inoculated with tumors. [Figure 6] Two synthetic routes based on acrylate and epoxyethyl groups are shown. [Figure 7A] The amine head and tail of the lipidoids used in the library screening are shown. [Figure 7B] This shows the IgG1 titers in the blood of mice vaccinated with different LNP / OVA complexes (n=2). [Figure 8] Typical OD values ​​for ELISA assays used to determine antibody titers are shown. [Figure 9A] Detailed sequences of primers for the gapdh, cxcl10, and ifnb1 genes are shown. [Figure 9B] This shows semi-quantitative PCR of target genes derived from DC2.4 cell mRNA. [Figure 10] TEM images of 93-O17S-F and 93-O17S-F / tumor lysate complexes are shown. [Figure 11] This provides gating information for evaluating the cellular composition of B16F10 tumors after in situ vaccination. [Figure 12] This shows the design of mRNA for vaccine design. [Modes for carrying out the invention]

[0014] In situ vaccination with a lipidoid nanosystem having enhanced cross-presentation and STING activation enhances the therapeutic efficacy against solid tumors. Herein, we have designed a lipidoid-based nanosystem that can enhance the effects of in situ vaccination by promoting the cross-presentation of TAAs and activation of the interferon gene (STING) pathway. As shown in Figure 1, a small amount of doxorubicin (DOX) is injected into the primary tumor to induce tumor immunogenic death and TAA release. 19Next, a lipidoid composition (e.g., nanoparticles) containing 2'5'-3'5' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) (LNP / cGAMP) is injected into the apoptotic site of the tumor to capture the released tumor antigen via electrostatic interaction. The LNP, containing both the tumor antigen and cGAMP, is delivered to antigen-presenting cells (APCs) via enhanced endocytosis. More importantly, the antigen and cGAMP can be released into the cytoplasm of the APC via the endo / lysosomal escape effect of the LNP. The released tumor antigen is then degraded by the ubiquitin-proteasome system and presented by major histocompatibility complex (MHC) class I, activating T cells. 20 cGAMP released into the cytoplasm can activate the STING pathway, as well as the production of type I interferon (IFN) and other pro-inflammatory cytokines, which also promote T cell activation. 21 The integration of enhanced cross-presentation and STING activation can facilitate in situ vaccination for tumor immunotherapy. Compared to oncolytic virus-based cancer immunotherapies, synthetic lipidoid compositions offer significant advantages, including a better safety profile and ease of mass production. Compared to other non-viral in situ vaccination systems, this system is advantageous in antigen capture, delivery, and cross-presentation, and therefore results in better therapeutic efficacy.

[0015] In one embodiment, the present disclosure provides a lipidoid composition comprising a plurality of lipidoids and an adjuvant, an antigen, or a nucleic acid.

[0016] In certain embodiments, each lipidoid independently comprises an amine head and a hydrophobic tail.

[0017] In certain embodiments, each amine head independently comprises an alkylamine, arylamine, heteroarylamine, or heterocyclylamine. In certain embodiments, each amine head independently comprises 1, 2, 3, 4, 5, 6, 7, or 8 nitrogen-containing moieties C4-C 20Contains an alkyl chain. In certain embodiments, each amine head independently contains 1, 2, 3, or 4 nitrogen-containing moieties C4-C 20 Contains alkyl chains.

[0018] In certain embodiments, the nitrogen-containing portion is a primary amine (e.g., NH2), an alkylamine (e.g., mono- or di-alkylamines such as mono- or dimethyl or mono- or diethylamine), a heteroaryl group (e.g., imidazole or pyridine), or a heterocyclyl group (e.g., piperidine or piperazine).

[0019] In certain embodiments, each amine head is independently substituted with alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amide, cyano, nitro, azide, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide. In certain embodiments, each amine head is substituted with hydroxyl.

[0020] In a particular embodiment, each amine head is independently, [ka] Or include pharmaceutically acceptable salts thereof, with each dashed line representing a connection (e.g., bond) to the hydrophobic tail.

[0021] In a particular embodiment, each amine head is independently, [ka] Or include pharmaceutically acceptable salts thereof, with each dashed line representing a connection (e.g., bond) to the hydrophobic tail.

[0022] In a particular embodiment, each amine head is independently, [ka] or a pharmaceutically acceptable salt thereof, and the dashed line represents a connection (e.g., a bond) to the hydrophobic tail.

[0023] In certain embodiments, each amine head is independently

Chemical Structure

[0024] In certain embodiments, each amine head is independently

Chemical Structure

[0025] In certain embodiments, each amine head is independently

Chemical Structure

[0026] In certain embodiments, each hydrophobic tail is independently a C1 - C 30 alkyl chain, a C1 - C 30 alkyl acyl (e.g., a C4 - C 30 alkyl acyl, a C6 - C 30 alkyl acyl, a C4 - C 25 alkyl acyl, a C6 - C 25 alkyl acyl, a C4 - C 20 alkyl acyl, a C6 - C 20 alkyl acyl, a C4 - C 18 alkyl acyl, or a C6 - C 18 alkyl acyl) chain, a C1 - C 30 alkyl ester (e.g., a C4 - C 30 alkyl ester, a C6 - C 30 alkyl ester, a C4 - C 25Alkyl esters, C6-C 25 Alkyl esters, C4-C 20 Alkyl esters, C6-C 20 Alkyl esters, C4-C 18 Alkyl esters, or C6-C 18 Alkyl ester chain, or C1-C 30 Alkylamides (for example, C4~C 30 Alkylamide, C6~C 30 Alkylamide, C4~C 25 Alkylamide, C6~C 25 Alkylamide, C4~C 20 Alkylamide, C6~C 20 Alkylamide, C4~C 18 alkylamide, or C6-C 18 Contains an alkylamide chain. In certain embodiments, each hydrophobic tail is independently C1-C 30 Alkyl (for example, C4~C 30 Alkyl, C6~C 30 Alkyl, C4~C 25 Alkyl, C6~C 25 Alkyl, C4~C 20 Alkyl, C6~C 20 Alkyl, C4~C 18 Alkyl, or C6-C 18 Alkyl chain, C1-C 30 Alkyl esters (for example, C4-C 30 Alkyl esters, C6-C 30 Alkyl esters, C4-C 25 Alkyl esters, C6-C 25 Alkyl esters, C4-C 20 Alkyl esters, C6-C 20 Alkyl esters, C4-C 18 Alkyl esters, or C6-C 18 Alkyl ester chain, or C1-C 30 Alkylamides (for example, C4~C 30 Alkylamide, C6~C 30 Alkylamide, C4~C 25 Alkylamide, C6~C 25 Alkylamide, C4~C20 alkylamide, C6 - C 20 alkylamide, C4 - C 18 alkylamide, or C6 - C 18 alkylamide) chain.

[0027] In certain embodiments, at least one carbon atom of C1 - C 30 alkyl (e.g., C4 - C 30 alkyl, C6 - C 30 alkyl, C4 - C 25 alkyl, C6 - C 25 alkyl, C4 - C 20 alkyl, C6 - C 20 alkyl, C4 - C 18 alkyl, or C6 - C 18 alkyl) is replaced by a heteroatom. In certain embodiments, at least one carbon atom of C1 - C 30 alkyl (e.g., C4 - C 30 alkyl, C6 - C 30 alkyl, C4 - C 25 alkyl, C6 - C 25 alkyl, C4 - C<00\00075>alkyl, C6 - C 20 alkyl, C4 - C 18 alkyl, or C6 - C 18 alkyl) is replaced by 1, 2, 3, 4, 5, 6, 7, or 8 heteroatoms. In certain embodiments, at least one carbon atom of C1 - C 30 alkyl (e.g., C4 - C 30 alkyl, C6 - C 30 alkyl, C4 - C 25 alkyl, C6 - C 25 alkyl, C4 - C 20 alkyl, C6 - C 20 alkyl, C4 - C 18 alkyl, or C6 - C 18 alkyl) is replaced by a heteroatom. In certain embodiments, at least one carbon atom of C1 - C 30 alkyl (e.g., C4 - C 30 alkyl, C6 - C 30 alkyl, C4 - C 25 alkyl, C6 - C25 Alkyl, C4~C 20 Alkyl, C6~C 20 Alkyl, C4~C 18 Alkyl, or C6-C 18 The two carbon atoms in an alkyl group are replaced by heteroatoms.

[0028] In a particular embodiment, each heteroatom is independently selected from the group consisting of N (e.g., NH), O, S, and Se. In a particular embodiment, each heteroatom is independently selected from the group consisting of O, S, and Se. In a particular embodiment, each heteroatom is independently selected from the group consisting of O, S, and Se. In a particular embodiment, each heteroatom is O. In a particular embodiment, each heteroatom is S. In a particular embodiment, each heteroatom is Se.

[0029] In certain embodiments, each hydrophobic tail is independently substituted with alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amide, cyano, nitro, azide, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide. In certain embodiments, each hydrophobic tail is independently substituted with halo (e.g., fluoro).

[0030] In a particular embodiment, each hydrophobic tail portion is independently represented by the following formula: [ka] Includes, During the ceremony, The dashed line represents a bond to the amine head (e.g., a bond). m1 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m2 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m3 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m4 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m5 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m6 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n1 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n2 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n3 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n4 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n5 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n6 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n7 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); and n8 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15).

[0031] In certain embodiments, each hydrophobic tail portion is independently, [ka] The dashed line indicates a connection (e.g., bond) to the amine head.

[0032] In certain embodiments, each hydrophobic tail portion is [ka] The dashed line indicates a connection (e.g., bond) to the amine head.

[0033] In certain embodiments, the alkyl chain is substituted with a halo (e.g., a fluoro).

[0034] In certain embodiments, each hydrophobic tail portion is [ka] The dashed line indicates a connection (e.g., bond) to the amine head.

[0035] In certain embodiments, the alkyl chain is substituted with a halo (e.g., a fluoro).

[0036] In a particular embodiment, each hydrophobic tail portion is independently represented by the following formula: [ka] Essentially, During the ceremony, The dashed line represents a bond to the amine head (e.g., a bond). m1 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m2 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m3 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m4 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m5 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); m6 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n1 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n2 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n3 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n4 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n5 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n6 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); n7 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15); and n8 is an integer between 4 and 30 (or any subrange thereof, e.g., 4 to 25, 4 to 25, 6 to 25, 4 to 20, 6 to 20, 4 to 18, 6 to 18, 4 to 15, or 6 to 15).

[0037] In certain embodiments, each hydrophobic tail portion is independently, [ka] Essentially, it becomes, and the dashed line represents a connection (e.g., bond) to the amine head.

[0038] In certain embodiments, each hydrophobic tail portion is [ka] Essentially, it becomes, and the dashed line represents a connection (e.g., bond) to the amine head.

[0039] In certain embodiments, the alkyl chain is substituted with a halo (e.g., a fluoro).

[0040] In certain embodiments, each hydrophobic tail portion is [ka] Essentially, it becomes, and the dashed line represents a connection (e.g., bond) to the amine head.

[0041] In certain embodiments, the alkyl chain is substituted with a halo (e.g., a fluoro).

[0042] In certain embodiments, multiple lipidoids form a bilayer.

[0043] In certain embodiments, immunomodulators stimulate innate immunity. In certain embodiments, immunomodulators can stimulate one or more immune-related genes. In certain embodiments, immunomodulators can inhibit one or more immune-related genes. In certain embodiments, immunomodulators are immune enhancers. In certain embodiments, immunomodulators are immune inhibitors. In certain embodiments, immunomodulators are interferon gene stimulants (STINGs). In certain embodiments, STINGs are STING agonists. In certain embodiments, STING agonists are cyclic dinucleotides. In certain embodiments, STING agonists are cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).

[0044] In certain embodiments, the immunomodulator is encapsulated within a lipidoid composition. In certain embodiments, multiple lipidoids form a bilayer, and the immunomodulator is encapsulated within the bilayer.

[0045] In certain embodiments, the lipidoid composition includes an adjuvant. In certain embodiments, the adjuvant is an immune system stimulator. In certain embodiments, the immune system stimulator stimulates innate immunity. In certain embodiments, the immune system stimulator is an interferon gene stimulator (STING). In certain embodiments, the STING is a STING agonist. In certain embodiments, the STING agonist is a cyclic dinucleotide. In certain embodiments, the STING agonist is cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).

[0046] In certain embodiments, the adjuvant is encapsulated within the lipidoid composition. In certain embodiments, multiple lipidoids form a bilayer, and the adjuvant is encapsulated within the bilayer.

[0047] In certain embodiments, the lipidoid composition contains an antigen. In some embodiments, the antigen is a vaccine. In certain embodiments, the antigen is a protein. In certain embodiments, the antigen is a weakened virus.

[0048] In certain embodiments, the antigen is encapsulated within a lipidoid composition. In certain embodiments, multiple lipidoids form a bilayer, and the antigen is encapsulated within the bilayer.

[0049] In certain embodiments, the lipidoid composition contains nucleic acid. In certain embodiments, the nucleic acid is DNA or RNA. In certain embodiments, the nucleic acid is RNA. In certain embodiments, the RNA is mRNA.

[0050] In certain embodiments, when mRNA comes into contact with a cell, the mRNA induces the synthesis of a protein belonging to the cancer cell. In certain embodiments, the cancer cell is a bladder cancer cell, breast cancer cell, brain tumor cell, bone cancer cell, cervical cancer cell, colorectal cancer cell, head cancer cell, cervical cancer cell, kidney cancer cell, liver cancer cell, lung cancer cell, lymphoma cell, mesothelioma cell, myeloma cell, prostate cancer cell, skin cancer cell, thyroid cancer cell, ovarian cancer cell, or endometrial cancer cell.

[0051] In certain embodiments, mRNA comes into contact with a cell, and the mRNA induces the synthesis of proteins belonging to the virus. In some embodiments, the virus is hepatitis C virus, norovirus, junin virus, dengue virus, coronavirus, human immunodeficiency virus, herpes simplex virus, avian influenza virus, varicella virus, cold sores virus, common cold virus, glandular fever virus, influenza virus, measles virus, mumps virus, pharyngitis virus, pneumonia virus, rubella virus, severe acute respiratory syndrome virus, and lower or upper respiratory tract infection viruses (e.g., respiratory syncytial virus). In some embodiments, the virus is influenza virus. In some embodiments, the virus is human immunodeficiency virus. In certain embodiments, the virus is coronavirus. In certain embodiments, the coronavirus is SARS-CoV-2. In certain embodiments, SARS-CoV-2 is an alpha, beta, gamma, delta, or omicron strain of SARS-CoV-2. In certain embodiments, when mRNA comes into contact with a cell, the mRNA induces the synthesis of the SARS-CoV-2 spike protein.

[0052] In certain embodiments, the mRNA has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence shown in Figure 12. In certain embodiments, the mRNA has at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence shown in Figure 12. In certain embodiments, the mRNA has at least 90%, 95%, or 99% sequence identity to the sequence shown in Figure 12. In certain embodiments, the mRNA has at least 95% or 99% sequence identity to the sequence shown in Figure 12. In certain embodiments, the mRNA has a sequence that conforms to the sequence shown in Figure 12.

[0053] In certain embodiments, the lipidoid composition further comprises a chemotherapeutic agent. In certain embodiments, the chemotherapeutic agent is cytotoxic. In certain embodiments, the chemotherapeutic agent is an alkylating agent, an antimetabolite, an anti-microtubule agent, an antitumor antibiotic, or a topoisomerase inhibitor, a mitotic inhibitor, or a corticosteroid. In certain embodiments, the chemotherapeutic agents include altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechloretamine, melphalan, oxaliplatin, temozolomide, thiotepa, trabectedin, carmustine, lomustine, streptozosin, azacitidine, 5-fluorouracil (5-Fu), 6-mercaptopurine (6-MP), capecitabine, cladribine, clopharabine, cytarabine (Ara-C), decitabine, phloxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, and trifluri. These include din, tipiracil, daunorubicin, doxorubicin, doxorubicin liposome, epirubicin, idarubicin, barurubicin, bleomycin, dactinomycin, mitomycin-C, mitoxantrone, irinotecan, irinotecan liposome, topotecan, etoposide, mitoxantrone, teniposide, cabazitaxel, docetaxel, nab-paclitaxel, paclitaxel, vinblastine, vincristine, vincristine liposome, vinorelbine, prednisone, methylprednisolone, dexamethasone, retinoic acid, arsenic trioxide, asparaginase, eribulin, hydroxyurea, ixabepyrone, mitotane, omasetaxin, pegaspargase, procarbazine, romidepsin, or vorinostat. In one aspect, the chemotherapeutic agent is doxorubicin.

[0054] In certain embodiments, the lipidoid composition is assembled with an (endogenous or exogenous) antigen, an immunomodulator, an adjuvant, or any combination thereof. In certain embodiments, the lipidoid composition is assembled with an (endogenous or exogenous) antigen. In certain embodiments, the lipidoid composition is assembled with an immunomodulator. In certain embodiments, the lipidoid composition is assembled with an (endogenous or exogenous) antigen and an immunomodulator. In certain embodiments, the lipidoid composition is assembled with an adjuvant.

[0055] In certain embodiments, the lipidoid composition can internalize an antigen (e.g., an antigen derived from tumor cells).

[0056] In another aspect, the present disclosure provides a pharmaceutical composition comprising a lipidoid composition and a pharmaceutically acceptable excipient disclosed herein.

[0057] In another aspect, the Disclosure provides a method for treating cancer in a target subject of interest, comprising administering a therapeutically effective amount of a lipidoid composition disclosed herein.

[0058] In certain embodiments, the lipidoid composition is administered topically. In certain embodiments, the lipidoid composition is administered systemically. In certain embodiments, the lipidoid composition is administered intratumorally, intradermally, or intramuscularly. In certain embodiments, the lipidoid composition is administered intratumorally. In certain embodiments, the lipidoid composition is administered intradermally. In certain embodiments, the lipidoid composition is administered intramuscularly.

[0059] In certain embodiments, the lipidoid composition can internalize an antigen (e.g., an antigen derived from tumor cells).

[0060] In another aspect, the present disclosure provides a pharmaceutical composition comprising a lipidoid composition and a pharmaceutically acceptable excipient disclosed herein.

[0061] In another aspect, the Disclosure provides a method for treating cancer in a target subject of interest, comprising administering a therapeutically effective amount of a lipidoid composition disclosed herein.

[0062] In certain embodiments, the lipidoid composition is administered into the tumor.

[0063] In certain embodiments, the lipidoid composition is administered topically. In certain embodiments, the lipidoid composition is administered systemically. In certain embodiments, the lipidoid composition is administered intratumorally, intradermally, or intramuscularly. In certain embodiments, the lipidoid composition is administered intratumorally. In certain embodiments, the lipidoid composition is administered intradermally. In certain embodiments, the lipidoid composition is administered intramuscularly.

[0064] In a certain manner, cancer is a solid tumor. In a particular manner, cancer is bladder cancer, breast cancer, brain tumor, bone cancer, cervical cancer, colorectal cancer, head cancer, neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, mesothelioma, myeloma, prostate cancer, skin cancer, thyroid cancer, ovarian cancer, or uterine cancer.

[0065] In certain embodiments, this method induces an anti-cancer immune response in the subject.

[0066] In another aspect, the Disclosure provides a method for treating cancer in a target subject, comprising the steps of: administering a therapeutically effective amount of a chemotherapeutic agent to a target; and administering a therapeutically effective amount of a lipidoid composition disclosed herein to a target.

[0067] In certain embodiments, the chemotherapeutic agent is cytotoxic.

[0068] In certain embodiments, the chemotherapeutic agent is an alkylating agent, an antimetabolite, an antimicrotubule agent, an antitumor antibiotic, or a topoisomerase inhibitor, a mitotic inhibitor, or a corticosteroid.

[0069] In certain embodiments, the chemotherapeutic agents include altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechloretamine, melphalan, oxaliplatin, temozolomide, thiotepa, trabectedin, carmustine, lomustine, streptozosin, azacitidine, 5-fluorouracil (5-Fu), 6-mercaptopurine (6-MP), capecitabine, cladribine, clopharabine, cytarabine (Ara-C), decitabine, phloxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, and trifluri. These include din, tipiracil, daunorubicin, doxorubicin, doxorubicin liposome, epirubicin, idarubicin, barurubicin, bleomycin, dactinomycin, mitomycin-C, mitoxantrone, irinotecan, irinotecan liposome, topotecan, etoposide, mitoxantrone, teniposide, cabazitaxel, docetaxel, nab-paclitaxel, paclitaxel, vinblastine, vincristine, vincristine liposome, vinorelbine, prednisone, methylprednisolone, dexamethasone, retinoic acid, arsenic trioxide, asparaginase, eribulin, hydroxyurea, ixabepyrone, mitotane, omasetaxin, pegaspargase, procarbazine, romidepsin, or vorinostat.

[0070] In one aspect, the chemotherapeutic agent is doxorubicin.

[0071] In certain embodiments, the chemotherapeutic agent is administered locally. In certain embodiments, the chemotherapeutic agent is administered systemically. In certain embodiments, the chemotherapeutic agent is administered intratumorally.

[0072] In certain embodiments, the chemotherapeutic agent is administered locally. In certain embodiments, the chemotherapeutic agent is administered systemically. In certain embodiments, the chemotherapeutic agent is administered intratumorally.

[0073] In certain embodiments, the lipidoid composition is administered approximately 6 to 48 hours after the chemotherapeutic agent. In certain embodiments, the lipidoid composition is administered approximately 6 to 24 hours after the chemotherapeutic agent. In certain embodiments, the lipidoid composition is administered approximately 24 hours after the chemotherapeutic agent.

[0074] In one aspect, cancer is a solid tumor. In certain embodiments, cancer is bladder cancer, breast cancer, brain tumor, bone cancer, cervical cancer, colorectal cancer, head cancer, neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, mesothelioma, myeloma, prostate cancer, skin cancer, thyroid cancer, ovarian cancer, or uterine cancer.

[0075] In certain embodiments, this method induces an anti-cancer immune response in the subject.

[0076] In another aspect, the Disclosure provides a method for treating or preventing a viral infection in a subject of interest, comprising administering a therapeutically effective amount of the lipidoid composition disclosed herein to the subject.

[0077] In certain embodiments, the method treats a viral infection. In certain embodiments, the method prevents a viral infection.

[0078] In one embodiment, the viral infection is hepatitis C, norovirus, junin, dengue virus, coronavirus, human immunodeficiency virus, herpes simplex, avian influenza, varicella, herpes simplex, common cold, glandular fever, influenza, measles, mumps, pharyngitis, pneumonia, rubella, severe acute respiratory syndrome, and lower or upper respiratory tract infections (e.g., respiratory syncytial virus). In one embodiment, the viral infection is influenza virus. In one embodiment, the viral infection is human immunodeficiency virus infection. In one embodiment, the viral infection is coronavirus infection. In certain embodiments, the coronavirus is SARS-CoV-2. In certain embodiments, SARS-CoV-2 is the alpha, beta, gamma, delta, or omicron strain of SARS-CoV-2.

[0079] In certain embodiments, the method induces an immune response in the subject. In certain embodiments, the method induces an antiviral immune response in the subject.

[0080] In a particular embodiment, the method involves vaccinating a subject against a viral infection.

[0081] In another embodiment, the present disclosure provides a kit comprising a chemotherapeutic agent and a lipidoid composition disclosed herein.

[0082] In certain embodiments, the chemotherapeutic agent is cytotoxic.

[0083] In certain embodiments, the chemotherapeutic agent is an alkylating agent, an antimetabolite, an antimicrotubule agent, an antitumor antibiotic, or a topoisomerase inhibitor, a mitotic inhibitor, or a corticosteroid.

[0084] In certain embodiments, the chemotherapeutic agents include altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechloretamine, melphalan, oxaliplatin, temozolomide, thiotepa, trabectedin, carmustine, lomustine, streptozosin, azacitidine, 5-fluorouracil (5-Fu), 6-mercaptopurine (6-MP), capecitabine, cladribine, clopharabine, cytarabine (Ara-C), decitabine, phloxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, and triflu. Lysine, tipiracil, daunorubicin, doxorubicin, doxorubicin liposome, epirubicin, idarubicin, barurubicin, bleomycin, dactinomycin, mitomycin-C, mitoxantrone, irinotecan, irinotecan liposome, topotecan, etoposide, mitoxantrone, teniposide, cabazitaxel, docetaxel, nab-paclitaxel, paclitaxel, vinblastine, vincristine, vincristine liposome, vinorelbine, prednisone, methylprednisolone, dexamethasone, retinoic acid, arsenic trioxide, asparaginase, eribulin, hydroxyurea, ixabepyrone, mitotane, omasetaxin, pegaspargase, procarbazine, romidepsin, or vorinostat.

[0085] In one aspect, the chemotherapeutic agent is doxorubicin.

[0086] In another embodiment, the Disclosure provides a kit comprising a chemotherapeutic agent and a pharmaceutical composition comprising a lipidoid composition disclosed herein.

[0087] In certain embodiments, the chemotherapeutic agent is cytotoxic.

[0088] In certain embodiments, the chemotherapeutic agent is an alkylating agent, an antimetabolite, an antimicrotubule agent, an antitumor antibiotic, or a topoisomerase inhibitor, a mitotic inhibitor, or a corticosteroid.

[0089] In certain embodiments, the chemotherapeutic agents include altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechloretamine, melphalan, oxaliplatin, temozolomide, thiotepa, trabectedin, carmustine, lomustine, streptozosin, azacitidine, 5-fluorouracil (5-Fu), 6-mercaptopurine (6-MP), capecitabine, cladribine, clopharabine, cytarabine (Ara-C), decitabine, phloxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, and triflu. Lysine, tipiracil, daunorubicin, doxorubicin, doxorubicin liposome, epirubicin, idarubicin, barurubicin, bleomycin, dactinomycin, mitomycin-C, mitoxantrone, irinotecan, irinotecan liposome, topotecan, etoposide, mitoxantrone, teniposide, cabazitaxel, docetaxel, nab-paclitaxel, paclitaxel, vinblastine, vincristine, vincristine liposome, vinorelbine, prednisone, methylprednisolone, dexamethasone, retinoic acid, arsenic trioxide, asparaginase, eribulin, hydroxyurea, ixabepyrone, mitotane, omasetaxin, pegaspargase, procarbazine, romidepsin, or vorinostat.

[0090] In one aspect, the chemotherapeutic agent is doxorubicin.

[0091] Pharmaceutical composition The compositions and methods of the present invention may be used to treat individuals in need. The pharmaceutical compositions described herein may include therapeutic or prophylactic compositions, or any combination thereof. In some embodiments, the lipidoid composition may be assembled with an antigen, an immunomodulator, or any combination thereof. In certain embodiments, the individual is a mammal such as a human, or a non-human mammal. When administered to an animal such as a human, the composition or lipidoid composition is preferably administered as a pharmaceutical composition comprising, for example, the lipidoid composition of the present invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline, or other solvents or vehicles such as glycols, glycerols, oils (e.g., olive oil), or injectable organic esters. In preferred embodiments, if such a pharmaceutical composition is for human administration, particularly for invasive routes of administration (i.e., routes such as injection or implantation that avoid transport or diffusion through the epithelial barrier), the aqueous solution is pyrogen-free or substantially pyrogen-free. Excipients can be selected, for example, to provide delayed release of the drug or to selectively target one or more cells, tissues, or organs. Pharmaceutical compositions may be in the form of dosage units such as tablets, capsules (including sprinkle capsules and gelatin capsules), granules, lyophilized products for reconstitution, powders, solutions, syrups, suppositories, and injections. Compositions may also be present in transdermal delivery systems, such as skin patches. Compositions may also be present in solutions suitable for topical administration, such as lotions, creams, or ointments.

[0092] A pharmaceutically acceptable carrier may include, for example, a physiologically acceptable agent that acts to stabilize, increase the solubility of, or enhance the absorption of a lipidoid composition, such as the lipidoid composition of the present invention. Such physiologically acceptable agents include, for example, carbohydrates such as glucose, sucrose, or dextran; antioxidants such as ascorbic acid or glutathione; chelating agents; low molecular weight proteins; or other stabilizers or excipients. The selection of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition may be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical composition (preparation) may be, for example, a liposome or other polymer matrix in which the lipidoid composition of the present invention can be incorporated therein. For example, liposomes containing phospholipids or other lipids are relatively easy to prepare and administer, non-toxic, physiologically acceptable, and metabolizable carriers.

[0093] The term "pharmaceutically acceptable" is used herein to mean a lipidoid composition, material, composition and / or dosage form that is suitable for use in contact with human and animal tissues, in proportion to a reasonable benefit-to-risk ratio, without excessive toxicity, irritation, allergic reactions, or other problems or complications, within the bounds of reasonable medical judgment.

[0094] As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be compatible with the other components of the formulation and “acceptable” in the sense that it is not harmful to the patient. Some examples of substances that may serve as pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository wax; (9) peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, and corn oil. Oils such as oils and soybean oil; (10) Glycols such as propylene glycol; (11) Polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) Esters such as ethyl oleate and ethyl laurate; (13) Agar; (14) Buffers such as magnesium hydroxide and aluminum hydroxide; (15) Alginic acid; (16) Pyrogen-free water; (17) Isotonic saline; (18) Ringer's solution; (19) Ethyl alcohol; (20) Phosphate buffer; and (21) Other non-toxic suitable substances used in pharmaceutical formulations.

[0095] Pharmaceutical compositions (preparations) can be administered to a target by any of a number of routes of administration, including, for example, oral (e.g., aqueous or non-aqueous solutions or suspensions such as liquid drugs, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingual); subcutaneous; transdermal (e.g., as a patch applied to the skin); and topical (e.g., as a cream, ointment, or spray applied to the skin). Lipidoid compositions may also be formulated for inhalation. In certain embodiments, lipidoid compositions may be simply dissolved or suspended in sterile water. Details of suitable administration routes and compositions thereof can be found, for example, in U.S. Patents 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970, and 4,172,896, and the patents cited herein.

[0096] The formulation can be conveniently provided in unit dosage forms and can be prepared by any method well known in the field of pharmacy. The amount of active ingredient that can be combined with a carrier material to make a single dosage form varies depending on the host being treated and the specific mode of administration. The amount of active ingredient that can be combined with a carrier material to make a single dosage form is generally the amount of lipidoid composition that produces the therapeutic effect. Generally, out of 100%, this amount is in the range of about 1% to about 99% of the active ingredient, preferably about 5% to about 70%, and most preferably about 10% to about 30%.

[0097] Methods for preparing these formulations or compositions include the step of associating an active composition, such as a lipidoid (e.g., nanoparticle) composition described herein, with a carrier and optionally one or more auxiliary components. Generally, formulations are prepared by homogeneously and closely associating a lipidoid (e.g., nanoparticle) composition described herein with a liquid carrier, a fine solid carrier, or both, and then, if necessary, shaping the product.

[0098] Formulations of the present invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavoring base, usually sucrose and acacia or tragacanth), lyophilized products, powders, granules, or as solutions or suspensions in aqueous or non-aqueous liquids, or as oil-in-water or water-in-oil liquid emulsions, or as elixirs or syrups, or as flavored tablets (using an inert base such as gelatin and glycerin, or sucrose and acacia), and / or as mouthwash, each containing a predetermined amount of the lipidoid (e.g., nanoparticles) composition of the present invention as described herein as an active ingredient. The lipidoid composition may also be administered as a bolus, lick, or paste.

[0099] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, sugar-coated tablets, powders, granules, etc.), the active ingredient is mixed with sodium citrate or dicalcium phosphate and / or one or more pharmaceutically acceptable carriers: (1) fillers or bulking agents such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants such as glycerol; (4) Disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) Dissolution retarders such as paraffin; (6) Absorption enhancers such as quaternary ammonium compounds; (7) Wetting agents such as cetyl alcohol and glycerol monostearate; (8) Adsorbents such as kaolin and bentonite clay; (9) Lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; (10) Complexing agents such as modified and unmodified cyclodextrins; and (11) Colorants. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical composition may also include buffers. Similar types of solid compositions may also be used as fillers in soft and hard-filled gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol.

[0100] Tablets may be prepared by compression or molding, sometimes with one or more auxiliary components. Compressed tablets may be prepared using a binder (e.g., gelatin or hydroxypropyl methylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate or cross-linked carboxymethylcellulose sodium), a surfactant, or a dispersant. Molded tablets may be prepared by molding a mixture of powdered lipidoid compositions moistened with an inert liquid diluent using appropriate machinery.

[0101] Tablets, as well as other solid dosage forms of pharmaceutical compositions such as sugar-coated tablets, capsules (including sprinkle capsules and gelatin capsules), pills and granules, can optionally be prepared by notching or using coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulation field. These can also be formulated to provide sustained or controlled release of the active ingredient therein, for example, by using varying proportions of hydroxypropyl methylcellulose, other polymer matrices, liposomes and / or microspheres to provide a desired release profile. They can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating a sterilizer in the form of a sterile solid composition that can be dissolved in sterile water or some other sterile injection medium immediately before use. These compositions may also optionally contain an opaque agent and may be compositions that release the active ingredient only in or preferentially in a delayed manner in a specific part of the gastrointestinal tract. Examples of embedding compositions that can be used include polymer substances and waxes. The active ingredient may also be in a microencapsulated form together with one or more of the excipients, where appropriate.

[0102] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophilized products for reconstitution, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, liquid dosage forms may contain, for example, inert diluents commonly used in the art, such as water or other solvents, cyclodextrins and their derivatives, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, and sorbitan fatty acid esters, as well as mixtures thereof.

[0103] In addition to inert diluents, oral compositions may also contain adjuvants such as humectants, emulsifiers and suspending agents, sweeteners, flavoring agents, colorants, fragrances and preservatives.

[0104] In addition to the active lipidoid composition, the suspension may contain suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, hydroxyaluminum oxide, bentonite, agar and tragacanth, and mixtures thereof.

[0105] Dosage forms for topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. Active lipidoid compositions can be mixed under sterile conditions with pharmaceutically acceptable carriers and any preservatives, buffers, or propellants as needed.

[0106] Ointments, pastes, creams, and gels may contain, in addition to the active lipidoid composition, excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, and zinc oxide, or mixtures thereof.

[0107] Powders and sprays may contain, in addition to the active lipidoid composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures thereof. Sprays may further contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane.

[0108] Transdermal patches offer the additional advantage of providing controlled delivery of the lipidoid composition of the present invention to the body. Such dosage forms can be prepared by dissolving or dispersing the active lipidoid composition in a suitable medium. Absorption enhancers can also be used to increase the flux of the lipidoid composition across the skin. The rate of such flux can be controlled by providing a rate-controlled membrane or by dispersing the lipidoid composition in a polymer matrix or gel.

[0109] As used herein, the terms “parenteral administration” and “administered parenterally” mean, but are not limited to, modes of administration other than enteral and topical administration, usually by injection, including, but not limited to, intravenous, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intraspinal, and intrasternal injections and infusions. Pharmaceutical compositions suitable for parenteral administration comprise one or more active lipidoid compositions in combination with one or more pharmaceutically acceptable sterile isotonic or non-aqueous solutions, dispersions, suspensions, or emulsions, or sterile powders that can be reconstituted into sterile injection solutions or dispersions immediately before use, which may contain antioxidants, buffers, bacteriostatic agents, solutes to make the formulation isotonic with the blood of the recipient to whom the formulation is intended, or suspending agents or thickeners.

[0110] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (such as glycerol, propylene glycol, and polyethylene glycol), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Appropriate fluidity can be maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.

[0111] These compositions may also contain adjuvants such as preservatives, humectants, emulsifiers, and dispersants. Prevention of microbial action can be ensured by including various antimicrobial and antifungal agents, such as parabens, chlorobutanol, and phenolsorbic acid. It may also be desirable to include isotonic agents such as sugars and sodium chloride in the composition. Furthermore, long-term absorption of injectable pharmaceutical formulations can be achieved by including absorption-delaying agents such as aluminum monostearate and gelatin.

[0112] In some cases, it is desirable to delay the absorption of a drug from subcutaneous or intramuscular injection in order to prolong its effects. This can be achieved by using a liquid suspension of a low-water-soluble crystalline or amorphous material. In this case, the absorption rate of the drug depends on its dissolution rate, which may depend on the crystal size and morphology. Alternatively, delayed absorption of parenterally administered drug formulations can be achieved by dissolving or suspending the drug in an oily vehicle.

[0113] Injectable depot formulations are prepared by forming a microencapsulation matrix of the lipidoid composition of the present invention within a biodegradable polymer such as polylactide-polyglycolide. The drug release rate can be controlled depending on the drug-to-polymer ratio and the properties of the specific polymer used. Other examples of biodegradable polymers include poly(orthoester) and poly(anhydride). Injectable depot formulations are also prepared by encapsulating the drug in liposomes or microemulsions that are compatible with body tissues.

[0114] For use in the method of the present invention, the active lipidoid composition can be provided either by itself or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably 0.5 to 90%) of the active ingredient in combination with a pharmaceutically acceptable carrier.

[0115] The delivery method can also be provided by rechargeable or biodegradable devices. In recent years, various sustained-release polymer devices for controlled delivery of drugs, including protein-based biologics, have been developed and tested in vivo. Various biocompatible polymers (including hydrogels), including both biodegradable and non-biodegradable polymers, can be used to form implants for the sustained release of lipidoid compositions at specific target sites.

[0116] The actual dose level of the active ingredient in a pharmaceutical composition may be varied to obtain an amount of the active ingredient that is effective in achieving the desired therapeutic response for a particular patient, composition, and mode of administration without causing toxicity to the patient.

[0117] The selected dosage level depends on a variety of factors, including the activity of the specific lipidoid composition or combination of lipidoid compositions used, or their esters, salts, or amides; the route of administration; the time of administration; the excretion rate of the specific lipidoid composition used; the duration of treatment; other drugs, lipidoid compositions, and / or materials used in combination with the specific lipidoid composition used; the age, sex, weight, condition, overall health, and medical history of the patient being treated; and similar factors well known in the medical field.

[0118] A physician or veterinarian with ordinary art in the art can easily determine and prescribe the therapeutically effective dose of the required pharmaceutical composition. For example, a physician or veterinarian can start with a dose of the pharmaceutical composition or lipidoid composition at a lower level than required to achieve the desired therapeutic effect and gradually increase the dose until the desired effect is achieved. "Therapeutically effective dose" means a concentration of the lipidoid composition sufficient to produce the desired therapeutic effect. It is generally understood that the effective dose of a lipidoid composition varies depending on the subject's weight, sex, age, and medical history. Other factors that may affect the effective dose include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the lipidoid composition, and, if desired, another type of therapeutic agent administered with the lipidoid composition of the present invention. Larger total doses can be delivered by multiple doses of the drug. Methods for determining efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison's Principles of Internal Medicine 13 ed., 1814-1882, incorporated herein by reference).

[0119] Generally, the appropriate daily dose of the active lipidoid composition used in the compositions and methods of the present invention is the amount of lipidoid composition that is the minimum effective dose to produce a therapeutic effect. Such an effective dose usually depends on the factors mentioned above.

[0120] If desired, an effective daily dose of the active lipidoid composition may be administered as one, two, three, four, five, six or more subdoses, administered separately at appropriate intervals throughout the day, or, if necessary, in unit dosage form. In certain embodiments of the present invention, the active lipidoid composition may be administered twice or three times daily. In preferred embodiments, the active lipidoid composition is administered once daily.

[0121] Patients receiving this treatment include any animal in need, such as primates, especially humans; as well as other mammals such as horses, cattle, pigs, sheep, cats and dogs; poultry; and pets in general.

[0122] In certain embodiments, the lipidoid composition of the present invention may be used alone or administered in combination with another type of therapeutic agent.

[0123] This disclosure includes the use of pharmaceutically acceptable salts of the lipidoid composition of the present invention in the compositions and methods of the present invention. In certain embodiments, the salts intended for the present invention include, but are not limited to, alkyl, dialkyl, trialkyl, or tetraalkylammonium salts. In certain embodiments, examples of salts intended for the present invention include, but are not limited to, L-arginine, benenthamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydravamin, 1H-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, 1-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, examples of salts intended for the present invention include, but are not limited to, Na, Ca, K, Mg, Zn, or other metal salts.In certain embodiments, the salts intended for use in this invention include 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, 1-ascorbic acid, 1-aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecyl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, and galactaric acid. Examples of undecylenic acid salts include, but are not limited to, gentisic acid, d-glucoheptonic acid, d-gluconic acid, d-glucuronic acid, glutamic acid, glutaric acid, glycerophosphate, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, 1-malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, 1-pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, 1-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenic acid salts.

[0124] Pharmacopoecially acceptable acid addition salts may also exist as various solvates with water, methanol, ethanol, dimethylformamide, and others. Mixtures of such solvates can also be prepared. The source of such solvates may be derived from the crystallization solvent, inherent in the preparation or crystallization solvent, or associated with such solvent.

[0125] Wetting agents, emulsifiers, and lubricants (e.g., sodium lauryl sulfate and magnesium stearate), as well as colorants, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives, and antioxidants may also be present in the composition.

[0126] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants such as ascorbic acid, cysteine ​​hydrochloride, sodium bicarbonate, sodium metabisulfite, and sodium sulfite; (2) oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, and α-tocopherol; and (3) metal chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, and phosphoric acid.

[0127] definition Unless otherwise defined herein, scientific and technical terms used herein shall have the meanings commonly understood by those skilled in the art. Generally, the nomenclature and techniques used in relation to chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics, and protein and nucleic acid chemistry described herein are commonly known and practiced in the art.

[0128] The methods and techniques described herein are, unless otherwise indicated, carried out in accordance with conventional methods commonly known in the art and described in various general and more specific references cited and discussed herein. See, for example, “Principles of Neural Science”, McGraw-Hill Medical, New York, NY (2000); Motulsky, “Intuitive Biostatistics”, Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th ed.”, WH Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th ed.”, WH Freeman & Co., NY (1999); and Gilbert et al., “Developmental Biology, 6th ed.”, Sinauer Associates, Inc., Sunderland, MA (2000).

[0129] Chemical terms used herein, unless otherwise defined herein, are used in accordance with their prior art usage, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, CA (1985).

[0130] All of the above and any other publications, patents, and published patent applications referenced in this application are incorporated herein by reference. In case of any conflict, this specification shall prevail, including its specific definitions.

[0131] The term "agent" is used herein to refer to compounds (e.g., organic or inorganic compounds, mixtures of compounds, etc.), biomacromolecules (e.g., nucleic acids, antibodies (including parts thereof, as well as humanized, chimeric and human antibodies, and monoclonal antibodies), proteins or parts thereof, e.g., peptides, lipids, carbohydrates, etc.), or extracts made from biological materials such as bacteria, plants, fungi, or animals (especially mammals), cells, or tissues. Agents include, for example, agents with known structures and agents with unknown structures.

[0132] The terms "patient," "subject," or "individual" are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, domestic animals (including cattle and pigs), companion animals (e.g., dogs and cats), and rodents (e.g., mice and rats).

[0133] To “treat” a condition or patient means to take steps to obtain a beneficial or desired outcome, including clinical outcomes. Beneficial or desired clinical outcomes may include, but are not limited to, the alleviation or improvement of one or more symptoms or conditions, whether detectable or undetectable; a reduction in the severity of the disease; a stabilized (i.e., non-worsening) state of the disease; prevention of disease spread; a delay or slowing of disease progression; improvement or alleviation of the disease state; and remission (whether partial or total), whether detectable or undetectable. “Treatment” may also mean extending survival compared to the survival expected without treatment.

[0134] The term “preventing” is recognized and well understood in the art when used in relation to conditions such as local recurrence (e.g., pain), diseases such as cancer, complex syndromes such as heart failure, or any other medical condition, and includes the administration of a composition that reduces the frequency of symptoms of a medical condition or delays their onset in a subject compared to a subject not administered the composition. Thus, cancer prevention includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving prophylactic treatment by a statistically and / or clinically significant amount compared to an untreated control population, and / or delaying the appearance of detectable cancerous growths in a treated population compared to an untreated control population.

[0135] The “administration” of a substance, compound, or drug to a target, or their “administration,” can be carried out using one of the various methods known to those skilled in the art. For example, compounds or drugs can be administered intravenously, intra-arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, intraocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., via vascular ducts). Compounds or drugs can also be appropriately introduced by refillable or biodegradable polymer devices or other devices (e.g., patches and pumps) or formulations that provide sustained release, sustained release, or controlled release of the compound or drug. Administration can be, for example, one dose, multiple doses, and / or over one or more extended periods.

[0136] The appropriate method for administering a substance, compound, or drug to a subject depends, for example, on the subject's age and / or physical condition, as well as the chemical and biological properties of the compound or drug (e.g., solubility, digestibility, bioavailability, stability, and toxicity). In some embodiments, the compound or drug is administered orally to the subject, for example, by ingestion. In some embodiments, the orally administered compound or drug is in the form of a sustained-release or extended-release formulation, or is administered using a device for such sustained-release or extended-release.

[0137] As used herein, the term “conjoint administration” refers to any form of administration of two or more different therapeutic agents such that a second agent is administered while a previously administered therapeutic agent is still effective in the body (for example, the two agents are effective simultaneously in the patient, which may include a synergistic effect between the two agents). For example, different therapeutic compounds may be administered simultaneously or sequentially, either in the same formulation or in separate formulations. Thus, an individual receiving such treatment may benefit from the combined effects of different therapeutic agents.

[0138] The "therapeutic effective dose" of a drug or medication is the amount of the drug or medication that, when administered to a subject, produces the intended therapeutic effect. The complete therapeutic effect may not necessarily occur with a single dose, but may only occur after a series of doses. Therefore, the therapeutic effective dose may be administered in one or more doses. The exact effective dose required for a subject depends, for example, on the subject's size, health, and age, as well as the nature and severity of the condition being treated (e.g., cancer or MDS). Those skilled in the art can readily determine the effective dose for a given situation through routine experiments.

[0139] As used herein, the terms “optional” or “optionally” mean that the events or circumstances described below may or may not occur, and that the description includes both cases in which the events or circumstances occur and cases in which they do not occur. For example, “optionally substituted alkyl” means that the alkyl may be substituted, but also includes cases in which the alkyl is not substituted.

[0140] It is understood that the substituents and substitution patterns of the compounds of the present invention can be selected by those skilled in the art so as to result in chemically stable compounds that can be readily synthesized from readily available starting materials by techniques known in the art and the methods described hereinafter. When the substituent itself is substituted with a plurality of groups, it is understood that these plurality of groups may be on the same carbon or on different carbons as long as a stable structure is obtained.

[0141] As used herein, the term "optionally substituted" refers to the replacement of 1 to 6 hydrogen radicals in a given structure with radicals of specific substituents including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH2-O-alkyl, -OP(O)(O-alkyl)2 or -CH2-OP(O)(O-alkyl)2. Preferably, "optionally substituted" refers to the replacement of 1 to 4 hydrogen radicals in a given structure with the above substituents. More preferably, 1 to 3 hydrogen radicals are replaced by the above substituents. It should be understood that the substituents may be further substituted.

[0142] As used herein, the term "alkyl" refers to a C1-C 10 linear alkyl group or a C1-C 10This refers to saturated aliphatic groups, including but not limited to branched alkyl groups. Preferably, the "alkyl" group refers to a C1-C6 linear alkyl group or a C1-C6 branched alkyl group. Most preferably, the "alkyl" group refers to a C1-C4 linear alkyl group or a C1-C4 branched alkyl group. Examples of "alkyl" include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, neopentyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 1-octyl, 2-octyl, 3-octyl, or 4-octyl. The "alkyl" group may be optionally substituted.

[0143] The term "acyl" is recognized in the relevant art and refers to a group represented by the general formula hydrocarbyl C(O)-, preferably alkyl C(O)-.

[0144] The term "acylamino" is recognized in the relevant technical field and refers to an amino group substituted with an acyl group, which can be represented, for example, by the formula hydrocarbyl C(O)NH-.

[0145] The term "acyloxy" is recognized in the relevant technical field and refers to a group represented by the general formula hydrocarbyl C(O)O-, preferably alkyl C(O)O-.

[0146] The term "alkoxy" refers to an alkyl group that has an oxygen atom bonded to it. Representative alkoxy groups include methoxy, ethoxy, propoxy, and tert-butoxy.

[0147] The term "alkoxyalkyl" refers to an alkyl group substituted with an alkoxy group, and can be represented by the general formula alkyl-O-alkyl.

[0148] The term "alkyl" refers to saturated aliphatic groups, including linear alkyl groups, branched alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. In preferred embodiments, linear or branched alkyl groups have 30 or fewer carbon atoms in their skeleton (for example, C for linear groups). 1-30 Regarding branched chains, C 3-30 ), more preferably having 20 or fewer carbon atoms.

[0149] Furthermore, when the term "alkyl" is used herein, in the examples and claims, it is intended to include both unsubstituted alkyl groups and substituted alkyl groups, the latter of which refers to an alkyl moiety having substituents that replace hydrogens on one or more carbons of a hydrocarbon skeleton, and includes haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl.

[0150] "C x-y " or "C x ~C y The term "alkyl" means a group containing x to y carbon atoms in a chain, when used with chemical parts such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy. C0 alkyl indicates hydrogen if the group is at the terminal position, and a bond if it is in the interior. For example, C 1-6 Alkyl groups contain 1 to 6 carbon atoms in their chain.

[0151] As used herein, the term "alkylamino" refers to an amino group substituted with at least one alkyl group.

[0152] The term "alkylthio," as used herein, refers to a thiol group substituted with an alkyl group, and may be represented by the general formula alkylS-.

[0153] As used herein, the term "amide" refers to the following groups: [ka] [In the formula, R 9 and R 10 Each of these independently represents either a hydrogen atom or a hydrocarbyl group, or R 9 and R 10 These atoms, along with the N atoms to which they are bonded, complete a heterocycle with 4 to 8 atoms in the ring structure.

[0154] The terms "amine" and "amino" are recognized in the art and refer to both unsubstituted and substituted amines, as well as their salts, for example, [ka] [In the formula, R 9 , R 10 , and R 10 Each of the ' represents either a hydrogen atom or a hydrocarbyl group, or R 9 and R 10 These atoms, along with the N atoms to which they are bonded, complete a heterocycle with 4 to 8 atoms in the ring structure. This refers to the part represented by [the symbol / symbol].

[0155] As used herein, the term "aminoalkyl" refers to an alkyl group substituted with an amino group.

[0156] As used herein, the term "aralkyl" refers to an alkyl group substituted with an aryl group.

[0157] As used herein, the term “aryl” includes substituted or unsubstituted monocyclic aromatic groups in which each atom of the ring is carbon. Preferably, the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, and at least one of the rings is aromatic, for example, the other cyclic ring may be a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Examples of aryl groups include benzene, naphthalene, phenanthrene, phenol, and aniline.

[0158] The term "carbamate" is recognized in the relevant technical field and refers to the following groups: [ka] [In the formula, R 9 and R 10 Each of these independently represents either a hydrogen atom or a hydrocarbyl group.

[0159] As used herein, the term "carbocykrylalkyl" refers to an alkyl group substituted with a carbocyclic group.

[0160] The term "carbocyclic ring" includes monocyclic rings with 5 to 7 members and bicyclic rings with 8 to 12 members. Each ring in a bicyclic carbocyclic ring may be selected from saturated, unsaturated, and aromatic rings. A carbocyclic ring includes a bicyclic molecule in which one, two, or three or more atoms are shared between two rings. The term "condensed carbocyclic ring" refers to a bicyclic carbocyclic ring in which each ring shares two adjacent atoms with the other ring. Each ring in a condensed carbocyclic ring may be selected from saturated, unsaturated, and aromatic rings. In exemplary embodiments, an aromatic ring, such as phenyl, may be condensed with a saturated or unsaturated ring, such as cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated, and aromatic bicyclic rings is included in the definition of a carbocyclic ring, as long as the valence allows. Exemplary “carbocyclic” compounds include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octa-3-ene, naphthalene, and adamantane. Exemplary condensed carbocyclic compounds include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-1H-indene, and bicyclo[4.1.0]hepta-3-ene. The “carbocyclic” compounds may be substituted at any one or more positions where hydrogen atoms may be present.

[0161] As used herein, the term "carbocykrylalkyl" refers to an alkyl group substituted with a carbocyclic group.

[0162] The term "carbonate" is recognized in the relevant technical field and refers to the group -OCO2-.

[0163] As used herein, the term "carboxy" refers to the group represented by the formula -CO2H.

[0164] The term "cycloalkyl" includes substituted or unsubstituted non-aromatic monocyclic structures, preferably 4- to 8-membered rings, more preferably 4- to 6-membered rings. The term "cycloalkyl" also includes polycyclic ring systems having two or more cyclic rings, where two or more carbons are common to two adjacent rings, and at least one of the rings is cycloalkyl, with substituents (e.g., R) 100 The group is bonded to a cycloalkyl ring, and for example, the other cyclic ring may be a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Examples of heteroaryl groups include pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, benzozodioxane, and tetrahydroquinoline.

[0165] The term "ester" as used herein refers to the group -C(O)OR 9 It refers to R 9 This represents a hydrocarbyl group.

[0166] As used herein, the term “ether” refers to a hydrocarbyl group bonded to another hydrocarbyl group via oxygen. Therefore, the ether substituent of a hydrocarbyl group can be hydrocarbyl-O-. Ethers may be symmetric or asymmetric. Examples of ethers include, but are not limited to, heterocyclic-O-heterocyclic and aryl-O-heterocyclic groups. Ethers also include “alkoxyalkyl” groups, which can be represented by the general formula alkyl-O-alkyl.

[0167] As used herein, the terms halo and halogen mean halogens, including chloro, fluoro, bromo, and iodine.

[0168] The terms "heteroaralkyl" and "heteroaralkyl" as used herein refer to alkyl groups substituted with heteroaryl groups.

[0169] The terms "heteroaryl" and "hetalil" include substituted or unsubstituted aromatic monocyclic structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, wherein the ring structure contains at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terms "heteroaryl" and "hetalil" also include polycyclic ring systems having two or more cyclic rings, where two or more carbons are common to two adjacent rings, and at least one of the rings is heteroaromatic, for example, the other cyclic ring may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Examples of heteroaryl groups include pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine.

[0170] As used herein, the term "heteroatom" means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.

[0171] As used herein, the term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclic group.

[0172] The terms "heterocyclyl", "heterocyclic", and "heterocyclic ring" refer to a substituted or unsubstituted non-aromatic ring structure, preferably a 3- to 10-membered ring, more preferably a 3- to 7-membered ring, and the ring structure contains at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terms "heterocyclyl" and "heterocyclic ring" also include polycyclic ring systems having two or more cyclic rings, where two or more carbons are common to two adjacent rings and at least one of the rings is heterocyclic. For example, the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Examples of heterocyclyl groups include piperidine, piperazine, pyrrolidine, morpholine, lactone, lactam, etc.

[0173] The term "hydrocarbyl", as used herein, refers to a group bonded through a carbon atom that has no =O or =S substituents and typically has at least one carbon-hydrogen bond and a main carbon skeleton, but may optionally contain heteroatoms. Thus, groups such as methyl, ethoxyethyl, 2-pyridyl, and even trifluoromethyl are considered hydrocarbyl for the purposes of this application, but substituents such as acetyl (having an =O substituent on the linked carbon) and ethoxy (linked through oxygen rather than carbon) are not. Examples of hydrocarbyl groups include, but are not limited to, aryl, heteroaryl, carbocyclic, heterocyclic, alkyl, alkenyl, alkynyl, and combinations thereof.

[0174] The term "hydroxyalkyl", as used herein, refers to an alkyl group substituted with a hydroxy group.

[0175] The term "lower", when used in combination with chemical moieties such as acyl, acyloxy, alkyl, alkenyl, alkynyl or alkoxy, means a group containing 10 or fewer, preferably 6 or fewer atoms in the substituent. "Lower alkyl" refers to, for example, an alkyl group containing 10 or fewer, preferably 6 or fewer carbon atoms. In certain embodiments, an acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituent as defined herein is a lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents as in the description of hydroxyalkyl and aralkyl (in which case, for example, when counting the carbon atoms in the alkyl substituent, the atoms in the aryl group are not counted).

[0176] The terms "policyclic", "polycyclic" and "polycyclic ring system" refer to two or more rings (e.g., cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl) in which two or more atoms are common to two adjacent rings, e.g., the rings are "fused rings". Each of the rings of the polycycle may or may not be substituted. In certain embodiments, each ring of the polycycle contains 3 to 10, preferably 5 to 7 atoms in the ring.

[0177] The term "sulfate" is recognized in the art and refers to the group -OSO3H or a pharmaceutically acceptable salt thereof.

[0178] The term "sulfonamide" is recognized in the art and refers to a group represented by the following general formula.

Chemical formula

[0179] <000​

[0180] The term "sulfonate" is recognized in the art and refers to an SO3H group or a pharmaceutically acceptable salt thereof.

[0181] The term "sulfone" is recognized in the relevant technical field and refers to the group -S(O)2-.

[0182] The term "substituted" refers to a portion having a substituent that replaces a hydrogen on one or more carbon atoms of the skeleton. It will be understood that "substituted" or "substituted with" implies an implicit condition that such substitution is subject to the allowable valencies of the substituted atom and substituent, and that the substitution results in a stable compound that does not spontaneously undergo transformation, such as rearrangement, cyclization, or elimination. As used herein, the term "substituted" is intended to include all allowable substituents of an organic compound. In a broader embodiment, allowable substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. There may be one or more allowable substituents for a given organic compound, and they may be the same or different. For the purposes of the present invention, heteroatoms such as nitrogen may have any allowable substituents of the organic compounds described herein that satisfy the valencies of the hydrogen substituent and / or the heteroatom. Substituents may include any substituents described herein, e.g., halogens, hydroxyls, carbonyls (e.g., carboxyls, alkoxycarbonyls, formyls, or acyls), thiocarbonyls (e.g., thioesters, thioacetic acids, or thioformates), alkoxyls, phosphoryls, phosphates, phosphonates, phosphinates, aminos, amides, amidines, imines, cyanos, nitros, azides, sulfhydryls, alkylthios, sulfates, sulfonates, sulfamoyls, sulfonamides, sulfonyls, heterocyclyls, aralkyls, or aromatic or heteroaromatic moieties. It will be understood by those skilled in the art that substituted portions on a hydrocarbon chain may, where appropriate, be substituted themselves.

[0183] As used herein, the term "thioalkyl" refers to an alkyl group substituted with a thiol group.

[0184] The term "thioester," as used herein, refers to the group -C(O)SR 9 or -SC(O)R 9 This refers to R 9 This represents hydrocarbyl.

[0185] As used herein, the term "thioether" is equivalent to an ether in which oxygen is replaced by sulfur.

[0186] The term "urea" is recognized in the relevant technical field and can be represented by the following general formula. [ka] [In the formula, R 9 and R 10 [This independently represents hydrogen or hydrocarbyl.]

[0187] As used herein, the term “modulate” includes inhibition or suppression of a function or activity (such as cell proliferation), as well as enhancement of a function or activity.

[0188] The phrase "pharmaceutically acceptable" is recognized in the art. In certain embodiments, this term includes compositions, excipients, adjuvants, polymers, and other materials and / or dosage forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio, within the bounds of sound medical judgment.

[0189] "Pharmacologically acceptable salt" or "salt" is used herein to mean an acid addition salt or base addition salt that is suitable for or adapted to the treatment of a patient.

[0190] As used herein, the term “pharmaceutically acceptable acid addition salt” means any non-toxic organic or inorganic salt of any base compound disclosed herein. Exemplary inorganic acids that form suitable salts include hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, as well as metal salts such as sodium monohydrogen orthophosphate and potassium bisulfate. Exemplary organic acids that form suitable salts include mono-, di-, and tri-carboxylic acids such as glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, benzoic acid, phenylacetic acid, cinnamic acid, and salicylic acid, as well as sulfonic acids such as p-toluenesulfonic acid and methanesulfonic acid. Either mono or diate salts can be formed, and such salts may exist in hydrated, solvated, or substantially anhydrous forms. Generally, acid addition salts of compounds of formula I are more soluble in water and various hydrophilic organic solvents and generally exhibit higher melting points compared to their free base forms. The selection of appropriate salts is known to those skilled in the art. Other pharmaceutically unacceptable salts, such as oxalates, may also be used in the isolation of compounds of formula I, for example, for laboratory use or for subsequent conversion to pharmaceutically acceptable acid addition salts.

[0191] As used herein, the term “pharmaceutically acceptable base addition salt” means any non-toxic organic or inorganic base addition salt of any acidic compound disclosed herein. Examples of inorganic bases that form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Examples of organic bases that form suitable salts include aliphatic, alicyclic, or aromatic organic amines, such as methylamine, trimethylamine, and picoline or ammonia. The selection of suitable salts is known to those skilled in the art.

[0192] Many of the lipidoid compositions (e.g., nanoparticles) useful in the methods and compositions of the present disclosure have at least one stereocenter in their structure. This stereocenter may be present in the R or S configuration, and the R and S notations are used in accordance with the rules described in Pure Appl. Chem. (1976), 45, 11-30. The present disclosure contemplates all stereoisomeric forms, including enantiomeric and diastereomeric forms of compounds, salts, prodrugs, or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01 / 062726.

[0193] Some lipidoid compositions (e.g., nanoparticles) may also contain compounds that exist in tautomeric forms. Such forms are not explicitly shown in the formulas described herein but are intended to be included within the scope of the present disclosure.

[0194] As used herein, the phrase "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material useful in formulating a drug for medical or therapeutic use.

Examples

[0195] The present invention has been generally described and will be more readily understood by reference to the following examples, which are included for the sole purpose of exemplifying specific aspects and embodiments of the present invention and are not intended to limit the present invention.

[0196] Example 1: Exemplary vaccine preparation overview In situ vaccination is a promising strategy for cancer immunotherapy due to its convenience and ability to induce a large number of tumor antigens. However, progress in in situ vaccination is also hindered by poor cross-presentation of tumor antigens and the immunosuppressive tumor microenvironment. To balance the safety and efficacy of in situ vaccination, lipidoid nanoparticles (LNPs) were designed to enhance cross-presentation and STING activation. After library screening, 93-O17S-F was shown to promote both cross-presentation of tumor antigens and delivery of cGAMP (a STING agonist). Intratumoral injection of 93-O17S-F / cGAMP combined with doxorubicin pretreatment demonstrated superior antitumor efficacy, with an overall recovery rate of 35% in primary B16F10 tumors and a tumor-free rate of 71.2% in rechallenged B16F10 tumors.

[0197] Consideration The composition and structure of lipidoids significantly influence the adjuvant effects of LNPs, including antigen delivery and immunostimulation. The Ac combinatorial library strategy has been used to develop synthetic lipidoids with diverse structures and properties for drug delivery. Ideal lipid nanoparticles for cancer immunotherapy need to be able to i) capture released tumor antigens and deliver them to antigen-presenting cells with enhanced cross-presentation; and ii) induce immunostimulatory effects. To identify effective lipidoids, a rough screening of selected libraries was performed by evaluating the antibody response in C57BL / 6 mice after immunization with model antigen ovalbumin (OVA) formulated with different LNPs (Figure 1A). Eighteen different lipidoids with different head and tail structures were formulated separately with OVA (Figure 7A). Mice were immunized via a prime-boost immunization strategy with two injections on days 1 and 14, respectively. As shown in Figure 7B, lipopolysaccharide (LPS) was used as a positive control and showed a highly positive immunoglobulin G1 (IgG1) antibody response. However, OVA alone, without formulation, had a very low antibody response due to its low immunogenicity. Interestingly, two lipidoids with a 93-amine head, 93-O17S-F and 93-O17O-F, in the selected library showed an antibody response comparable to LPS. The detailed IgG1 and IgG2c antibody responses of these lipidoids were further evaluated. The IgG1 antibody was mainly CD4 + Induced by T helper type 2 (Th2) cells, but the IgG2c antibody is CD4 + Caused by T helper type 1 (Th1) cells 24Th1 cells can activate macrophages and generate memory T cells, which are crucial for tumor cell death. As shown in Figures 2B and 2C, total IgG and IgG1 responses were consistent with results from rough screening. The three lead LNPs showed much stronger antibody responses than OVA alone, as well as the US FDA-approved alum adjuvant. However, only 93-O17S-F elicited a high IgG2c response, indicating Th1 cell activation (Figure 2D). Furthermore, excipients in the LNP formulations also significantly influenced antibody production. Without helper lipids, including cholesterol and dioleoylphosphatidylethanolamine (DOPE), 93-O17S showed no antibody response at all. In short, 93-O17S (93-O17S-F), formulated with excipients, can induce robust Th1 and Th2 responses with much better efficacy than established alum adjuvants.

[0198] CD4 by 93-O17S-F + Apart from the successful activation of both Th1 and Th2 cells, LNPs also deliver tumor antigens into cells and CD8 via cross-presentation. + It also serves as a delivery vehicle to enhance T cell activation. Free antigens such as OVAs are degraded by enzymes in lysosomes and then bind to MHC II molecules, leading to a primarily antibody-based immune response. CD8 is known to be more important in fighting cancer when antigens delivered to the cytosol can be degraded by proteasomes and antigen-derived peptides can further bind to MHC I molecules. +This study enhances cross-presentation to T cells. Model OVA antigens were presented to cells using 93-O17S-F, and the cells were then stained with anti-mouse H-2Kb bound to SIINFEKL antibody after 24 hours of incubation. DC2.4 cells treated with free OVA were used as a control. As shown in Figures 2G and 2F, a fluorescence shift was observed in 93-O17S-F / OVA-treated cells compared to free OVA-treated cells. Mean fluorescence intensity (MFI), calculated by flow cytometry, confirmed enhanced expression of the SIINFEKL-MHC I complex in 93-O17S-F / OVA-treated cells, which was approximately 1.8 times higher than in the free OVA group. These results demonstrate enhanced cross-presentation of delivered antigens (OVA) using 93-O17S-F.

[0199] To further enhance immune stimulation for cancer immunotherapy, cGAMP, an agonist of the STING pathway, was selected and encapsulated in 93-O17S-F for intracellular delivery. Recognition of cGAMP by STING leads to activation of APC, production of IFN, and CD8 against tumor antigens. + This leads to T cell priming, which has proven to be extremely important in cancer immunotherapy. 26、27 Although cGAMP itself cannot freely pass through the cell membrane to reach the STING promoter on the endoplasmic reticulum, it was hypothesized that lipidoid nanoparticles such as 93-O17S-F could provide a carrier for cGAMP via electrostatic interactions, facilitating its intracellular delivery and activating the STING pathway (Figure 3A). To prove this hypothesis, fluorescein-labeled cGAMP (cGAMP Fluo The intracellular distribution of cGAMP was evaluated by confocal laser scanning microscopy (CLSM) using ). Fluo The sample was then enclosed in 93-O17S-F and subsequently infused with 200 ng / mL cGAMP in RAW264.7 and DC2.4 media. FluoIt was added at a dose equivalent to [value]. Figure 3B shows the enhanced endocytosis and endo / lysosome escape of cGAMP delivered by 93-O17S-F. cGAMP encapsulated in 93-O17S-F after 4 hours of incubation. Fluo This was observed as a strong green signal in both RAW264.7 and DC2.4 cells. However, free cGAMP Fluo In cells treated with cGAMP, due to low cell membrane permeability, Fluo The green signal was almost nonexistent. More importantly, Figure 3B showed that cGAMP could escape from the endo / lysosome into the cytoplasm of both RAW264.7 and DC2.4 cells. cGAMP release is crucial for the subsequent activation of STING located in the endoplasmic reticulum.

[0200] To evaluate the promotion of STING activation by cytoplasmic delivery of LNPs, the expression of the ifnb1 and cxcl10 genes was measured by real-time polymerase chain reaction (RT-PCR) in RAW264.7 and DC2.4 cells. The ifnb1 and cxcl10 genes are two key genes associated with STING activation, leading to the abundant secretion of type I IFN and pro-inflammatory cytokines. As shown in Figure 3C, ifnb1 gene expression in both RAW264.7 and DC2.4 cells treated with 93-O17S-F / cGAMP was approximately 6.9-fold and 6.4-fold, respectively, compared to expression in cells treated with PBS. Free cGAMP showed only a modest increase in ifnb1 expression due to its low penetration into the cell membrane. A similar trend was observed in cxcl10 gene expression in Figure 3D. 93-O17S-F / cGAMP dramatically increased the expression of the cxcl10 gene (more than 100-fold), further confirming the activation of the STING pathway. Finally, the secretion of IFN-β, a typical type I interferon, was measured after treatment with different cGAMP formulations (Figure 3E). Consistent with gene expression, 93-O17S-F / cGAMP induced higher concentrations of secreted IFN-β. IFN-β secretion continued to increase further up to 24 hours, while IFN-β concentrations in the other groups remained largely unchanged. Upregulated expression of STING activation-related genes and pro-inflammatory factors demonstrated that 93-O17S-F can enhance the activation of the STING pathway via enhanced cytoplasmic delivery.

[0201] One notable advantage of this design is that the LNPs can also capture and deliver tumor antigens released from tumor cells after treatment with small amounts of chemotherapeutic agents (Figure 4A). Antigen capture capability was initially investigated by changes in LNP size and zeta potential after incubation with tumor lysate. As shown in Figure 4B, the size of the LNP-tumor lysate complex increased dramatically with increasing weight ratio of LNP to tumor lysate, due to absorption or aggregation of the complex. At a weight ratio of 1:0.6, the size reached its maximum due to the limited capacity of the LNPs. Figure 10 shows transmission electron microscopy images of blank 93-S14-F alone or complexed with tumor lysate. Blank 93-S14-F showed a well-separated spherical morphology but formed clusters after mixing with tumor lysate. This demonstrated interaction between LNPs and tumor lysate. Furthermore, the zeta potential of 93-S14-F decreased from positive to negative charge with increasing weight ratio of LNP to tumor lysate. This indicates that the capture of tumor lysate (containing tumor antigens) is mediated by electrostatic interactions.

[0202] To evaluate whether such antigen capture and delivery to influx region lymph nodes occur in a complex in vivo environment, we used Alexa Fluor 647-conjugated OVA (OVA) as a model antigen. Alexa-647 We developed in vivo experiments on antigen capture and delivery using OVA. Alexa-647 The drug was subcutaneously injected into the right flank of mice to mimic the antigen released after DOX administration. Then, to capture the released model antigen, 93-O17S-F / cGAMP or a PBS control was administered via OVA. Alexa-647 The injection was administered at the same location (Figure 4C). Five hours after the second injection, the mice were imaged using an in vivo imaging system (IVIS). As shown in Figure 4C-ii, free OVA Alexa-647 The subsequent injection of PBS was primarily distributed to the bladder, suggesting rapid clearance of soluble proteins via urine. Alexa-647In mice treated with this method and subsequently injected with 93-O17S-F / cGAMP at the same spot, OVA was observed in the lymph nodes in the inflow region. Alexa-647 A fluorescence signal was observed. Lymph nodes in the inflow region of two groups were collected and imaged (Figure 4C). Free OVA Alexa-647 The fluorescence intensity of the lymph nodes in the inflow area of ​​mice injected with 93-017S-F / cGAMP after treatment was the same as that of free OVA at the same spot. Alexa-647 The fluorescence intensity was significantly higher than that of mice treated with PBS before being injected. This result suggests that LNPs such as 93-O17S-F can capture free proteins in tissues and transport them to aspiration lymph nodes. Such ability is useful for capturing tumor antigens from tumor lysates and presenting them to APCs in aspiration lymph nodes, which may enhance antitumor effects and reduce immune escape.

[0203] In summary, the 93-O17S-F nanoparticle formulation can capture protein antigens, enhance antigen cross-presentation, and simultaneously deliver the STING agonist cGAMP. As shown in Figure 4D, STING activation in vivo was further evaluated using the LNP formulation in C57BL / 6 mice carrying a B16F10 subcutaneous tumor. To create the tumor model, 5x10 5 B16F10 cells were injected into the right flank of 4-6 week old C57BL / 6 mice. The tumor was 60-80 mm in size. 3The mice were grown to a certain size and divided into five groups. On day 0, free DOX was injected directly into the tumors of three groups to induce immunogenic death and release a large amount of tumor-associated antigen (TAA). On day 1, solutions containing PBS, 93-O17S-F, free cGAMP, and formulated 93-O17S-F / cGAMP were injected into the same sites as the DOX injections. Six hours after the second injection, the tumors were harvested and the expression of the ifnb1 and cxcl10 genes was analyzed by RT-PCR. As shown in Figures 4E and 4F, compared to tumors treated with DOX alone, the expression of both ifnb1 and cxcl10 did not change significantly in tumors injected with PBS one day after DOX injection. Tumors treated with free cGAMP one day after DOX injection showed a slight increase in these two genes, indicating that in situ administration of a STING agonist only slightly activates the STING pathway. However, all 93-O17S-F / cGAMP-treated groups showed increased expression of the ifnb1 and cxcl10 genes compared to free cGAMP, regardless of whether DOX was administered before the second injection. DOX administration also enhanced, to some extent, the activation of the STING pathway by 93-O17S-F / cGAMP, which may be due to the released tumor antigens.

[0204] Successful activation of the STING pathway by the LNP system can also alter the immune cell composition of the tumor microenvironment. As shown in Figure 4G, activation of the STING pathway stimulated the secretion of pro-inflammatory factors, including numerous chemokines that can recruit various immune cells to the tumor site. To further evaluate the changes in cellular composition after treatment, tumors were harvested 48 hours after the second injection. The tumors were dissociated into single cells, stained with antibodies, and analyzed by flow cytometry (Figure 11). Treatment with DOX alone was observed to alter CD4 + T cells and CD8 + It did not produce significant changes in either T cell population (Figure 4H). Free cGAMP-treated tumors showed CD4 + T cells and CD8 +The study showed increases in both T cell populations, suggesting that STING agonist administration may indeed contribute to the immunotherapy of solid tumors. However, a significant increase in the T cell population was observed in 93-O17S-F / cGAMP-treated tumors, particularly in the DOX-pre-treated group, after inclusion in 93-O17S-F. Furthermore, the macrophage population showed a similar trend to the T cell population at the tumor site (Figure 41). However, the DC population did not show a significant change in either treatment group. The recruitment of T cells and macrophages was associated with the level of STING pathway activation, which may contribute to the therapeutic outcomes of this in situ vaccination strategy.

[0205] Finally, the antitumor effect of the LNP system was evaluated in a B16F10 xenograft tumor model. As shown in Figure 5A, B16F10 cells were subcutaneously injected into the right flank of the back. The tumor was 60-80 mm in size. 3 At maturity, the mice were divided into five groups: PBS, DOX, 93-O17S-F / cGAMP, DOX+cGAMP, and DOX+93-O17S-F / cGAMP. The DOX, DOX+cGAMP, and DOX+93-O17S-F / cGAMP groups were treated with DOX on day 0, and then with PBS, free cGAMP, or 93-O17S-F / cGAMP on days 1 and 5, respectively. Tumor images were taken on day 6, as shown in Figure 5B. Small ulcer formation was observed in the tumors after treatment in all groups, particularly in the DOX+93-O17S-F / cGAMP group. Of all the experimental groups, the tumors in the DOX+93-O17S-F / cGAMP group were the smallest, and some had tumors that were indistinguishable after treatment. Figure 5C shows the tumor volume curve up to the first 10 days. Tumors treated with PBS still grow very rapidly, reaching approximately 2,000 mm. 3 The tumors reached an average size. Treatment with DOX resulted in only slight inhibition of tumor growth due to induced apoptosis. A single dose of 93-017S-F / cGAMP or free DOX+cGAMP inhibited the tumors to some extent, but they continued to grow. Detailed tumor volumes for each mouse are shown in Figure 5D. The tumor volume of PBS-treated mice was 2,000 mm³ within 12 days. 3It exceeded [a certain value]. Free DOX only slightly slowed the rapid growth compared to the PBS group, and the tumor volume still quickly reached 2,000 mm². 3 Treatment with 93-O17S-F / cGAMP without DOX pretreatment showed slight inhibition of tumor growth prior to day 8, but still could not inhibit rapid tumor growth over the long term. The results demonstrated that 93-O17S-F / cGAMP can activate the STING pathway in tumors and inhibit tumor growth to some extent. However, long-term inhibition of tumors is still hindered by inadequately presented tumor antigens without prior induction by DOX. In the DOX+93-O17S-F / cGAMP group, most tumor growth was inhibited, and two of them were tumor-free at the end of the experiment. The survival rates of treated mice are shown in Figure 5E. All mice treated with PBS reached the human endpoint within 14 days. Administration of free DOX, 93-O17S-F / cGAMP, or DOX+cGAMP showed only slight improvement in survival, and all mice reached the human endpoint within 25 days. Mice treated with DOX+93-O17S-F / cGAMP showed significantly extended survival rates, with tumor eradication in 2 out of 7 mice within 30 days. The superior antitumor efficacy of the LNP system further confirmed the superiority of 93-O17S-F / cGAMP for in situ vaccination, due to enhanced cross-presentation and STING activation.

[0206] Details of the exemplary experiment ELISA assay The plate was coated overnight at 4°C with 20 μg / mL of OVA in 50 μL of sodium carbonate solution (pH 8.0). The plate was then washed three times with PBST (PBS containing 0.5% tween-20) and blocked with 5% bovine serum albumin solution (Sigma-Aldrich). Serum collected from immunized mice was diluted 1:100 to triplicate and added to the plate at room temperature for 2 hours. The plate was then washed three times and incubated with 100 μL of HRP-conjugated IgG, IgG1, and IgG2c antibodies (1:10,000 dilution) for a further 2 hours. The plate was washed three times with PBST and incubated with 100 μL of 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The reaction was stopped with 0.16 M sulfuric acid. Optical density (OD) values ​​at 450 nm were read using a BioTex microplate reader. As shown in Figure 8, the endpoint titer is defined as the reciprocal of the highest serum dilution that yields a reading above the cutoff.

[0207] Detection of MHC I complex bound to SIINFEKL 5x10 4 DC2.4 cells were cultured in 24-well plates for 24 hours. The cells were then incubated with OVA or 93-O17S-F at an equivalent dose of OVA (1 μg / ml) for 24 hours. The cells were harvested, washed with PBS, and stained with PE anti-SIINFEKL-conjugated mouse H-2Kb antibody in flow cytometry staining buffer (eBioscience) at 4°C for 2 hours. After washing the stained cells with PBS, they were detected using an Attume NxT flow cytometer. Data were analyzed using FlowJo-v10.

[0208] Cellular uptake of cGAMP 5xl0 4 RAW264.7 and DC2.4 cells were cultured in coverslips with four-well chambers. Free cGAMP Fluo Alternatively, 93-O17S-F / cGAMP FluoThe phosphate group was added to the culture medium at a dose equivalent to 200 ng / mL of cGAMP. After 4 hours of incubation, the medium was changed and incubated for a further 1 hour in fresh medium containing LysoTracker Red DND-99. The cells were then washed with PBS and fixed with 4% paraformaldehyde (PFA) solution for 10 minutes. The slices were then covered with Fluoroshield® supplemented with DAPI (Sigma-Aldrich). Images were taken using a Leica TCS SP8 microscope.

[0209] In vitro evaluation of ifnb1 and cxcl10 gene expression by RT-PCR 5 x 10 5 RAW264.7 and DC2.4 cells were cultured in 6-well plates for 24 hours. The cells were then treated for 4 hours with PBS, free cGAMP, 93-O17S-F, or 93-O17S-F / cGAMP at doses equivalent to 150 nM cGAMP. Total mRNA was isolated using TriPure reagent (Sigma-Aldrich) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using a high-capacity cDNA reverse transcription kit (Applied Biosystems). RT-PCR was performed using Applied Biosystems PowerUp® SYBR® Green Master Mix and detected using a BioRad CFX96 Touch real-time PCR detection system. Relative gene expression was analyzed using CFX maestro software.

[0210] In vivo antigen capture and delivery 50 μL of OVA with a concentration of 1 μg / μL Alexa-647 OVA was subcutaneously injected into the right flank of BALB / c mice. Five minutes after the first injection, 50 μL of PBS or 50 μL of 93-O17S-F / cGAMP containing 200 μg of LNP was subcutaneously injected at the site of the first injection. Alexa-647 The distribution and isolated inflow region lymph nodes were monitored using the IVIS Spectrum in vivo imaging system.

[0211] In vivo evaluation of ifnb1 and cxcl10 gene expression by RT-PCR. 5x10 5 B16F10 cells were inoculated into the right flank of 4-6 week old C57BL / 6 mice. The tumor was 60-80 mm in size. 3 The mice were allowed to grow until they reached a certain size. The mice were divided into five groups: PBS, free DOX (referred to as DOX), 93-O17S-F / cGAMP, free cGAMP after DOX administration (referred to as DOX+cGAMP), and 93-O17S-F / cGAMP after DOX administration (referred to as DOX+93-O17S-F / cGAMP). On day 0, DOX was administered directly to the tumors of three of the groups at a dose of 0.1 mg / kg body weight ((kgBW)). -1 A dose equivalent to the first injection was administered intratumorally. On day 1, a second injection containing PBS, 93-O17S-F LNP, free cGAMP, and formulated 93-O17S-F / cGAMP was administered intratumorally to the same site as the first injection, at a dose equivalent to 20 μg of cGAMP encapsulated in 400 μg of 93-O17S-F LNP per mouse. Six hours after the second injection, the tumor was harvested and total mRNA was isolated using TriPure reagent. Detailed RT-PCR was performed using the same procedure as before.

[0212] Regulation of immune cell composition in the tumor microenvironment A tumor model was constructed and treated in the same manner as described in Section 6. Forty-eight hours after the second injection, the tumor was harvested and suspended in a single-cell solution using a 40 μm strainer (Thermo-Fisher). The cells were collected, washed with PBS, and stained with fluorescent antibodies for CD4 (APC-Cy7), CD8a (PE-Cy5), CD45 (PE), CD3e (FITC), F4 / 80 (APC), and CD11c (APC) in flow cytometry staining buffer (eBioscience). The fluorescence signals were measured using an LSR-II flow cytometer (BD Biosciences). The data were analyzed using FlowJo-v10.

[0213] Treatment of B16F10 tumors with in situ vaccination The tumor model was constructed in the same manner as described in Section 6. Mice were divided into five groups, each containing PBS, DOX, 93-O17S-F / cGAMP, DOX+cGAMP, and DOX+93-O17S-F / cGAMP. On day 0, DOX was directly administered to the tumors of three groups at a dose of 0.1 mg / kg body weight ((kgBW)). -1 The mice were injected intratumorally at a dose equivalent to ) (of the given substance). On days 1 and 5, second and third injections containing PBS, 93-O17S-F LNP, free cGAMP, and formulated 93-O17S-F / cGAMP were injected intratumorally at the same site as the DOX injection, at a dose equivalent to 20 μg of cGAMP encapsulated in 400 μg of 93-O17S-F LNP per mouse. Tumor length (L) and width (W) were measured every other day, and the formula was: V = L x W 2 The tumor volume (V) was calculated using the formula / 2.

[0214] The tumor rechallenge experiment was conducted as follows: 20 mice were treated in the same manner as described above. For 30 days, tumor-free mice were given 2x10. 5 The B16F10 cells were re-inoculated and monitored for 90 days.

[0215] Example 2: Further preparation of the exemplary vaccine overview The pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is rapidly expanding, causing immense damage and economic losses worldwide. By the end of October 2020, the number of reported cases worldwide exceeded 44 million, with more than 1 million deaths. To date, 11 vaccines are participating in Phase III clinical trials. Among these vaccines, mRNA-based vaccines have shown significant advantages because they are based on precise yet adaptive antigen design, induce responses from both CTLs and nAbs, and avoid many of the shortcomings of other forms of vaccines (protein, inactivated virus, DNA, and viral vectors). However, the cytotoxic T cell response to the mRNA-1273 vaccine (Moderna Therapeutics) remained low in non-human primates. Therefore, we hypothesized that the addition of an adjuvant that enhances CTL production could upregulate the cytotoxic T cell response of mRNA vaccines. We screened a lipid library for in vivo mRNA delivery and successfully identified candidate lipidoids capable of delivering mRNA to macrophages and dendritic cells (DCs) in lymph nodes in the lymph aspiration region. Next, we incorporated the adjuvant Pam3CSK4 into LNPs and found that the addition of Pam3CSK4 increased luciferase mRNA expression in lymph nodes in the lymph aspiration region. We then evaluated vaccination using adjuvant-containing lipid nanoparticles.

[0216] Consideration Optimize the selection of T cell and B cell epitopes and antigen design. CD4 and CD8 T cell epitopes were computer-characterized and identified from SARS-CoV-2 using an ensemble of machine learning algorithms that consider viral sequence conservation, expression levels, glycosylation, structural constraints, and MHC allele distribution in human populations. The identified epitopes were validated in vitro using peripheral blood mononuclear cells from individuals in the SARS-CoV-2 recovery phase. The validated epitopes were constructed into mRNA for optimal expression, processing, and presentation.

[0217] Three mRNA candidates have been identified for vaccine design: 1. Full-length spike protein (S). Full-length spike protein (S) with two proline mutations. pp ). 3. Full-length spike protein with mutated fulin cleavage sites (S デルタ ).

[0218] We will deliver vaccine mRNA to dendritic cells in the lymph nodes of the influx region using novel synthetic lipid nanoparticles. A novel class of imidazole-containing lipids that target mRNA to DCs or influx region lymph nodes has been identified. The encoding mRNA is formulated into lipid nanoparticles (LNPs) using these novel lipids and other known lipids (mRNA-LNPs), and the delivery of mRNA to DCs in influx region lymph nodes, as well as the induction of CTL and nAb responses in HLA-A2 transgenic mice, are compared. Targeted delivery and immune responses are optimized using DC-targeting ligands.

[0219] Compared to ALC-0315 LNP used in Pfizer-biontech's BNT162b2 mRNA vaccine, the lipidoid composition described herein is prepared in which mRNA expression in the influx region lymph nodes is enhanced.

[0220] It enhances the nAb response mediated by Toll-like receptor (TLR) ligands. TLR ligands (Pam3CSK4 and poly(I:C)) have been identified that dramatically enhance the nAb response to protein-based dengue virus vaccines while reducing the non-neutralizing antibody response. We will construct these two TLR ligands individually and combine them with mRNA-LNPs to test whether they enhance the nAb response and reduce antibody-dependent enhancement. The underlying mechanisms of the enhanced nAb response will be investigated for further adjuvant optimization.

[0221] This study aims to determine whether a selective mRNA vaccine provides protection against SARS-CoV-2 infection in small animal models. ACE2 transgenic mice and hamsters are susceptible to SARS-CoV infection. ACE2 transgenic mice, hamsters, or ferrets will be vaccinated with the most optimized vaccine candidate, and the induction of an immune response will be evaluated by ELISA, SARS-CoV-2 neutralization assay, and CTL assay. The vaccinated animals will be challenged with SARS-CoV-2. Clinical signs, viral load, and animal health status will be monitored. Collectively, these data will enable the evaluation of vaccine efficacy in mitigating SARS-CoV-2 in relevant preclinical animal models.

[0222] Inclusion by reference All publications and patents referenced herein are incorporated herein by whole, as if each individual publication or patent were specifically and individually incorporated by reference. In case of any conflict, the present application, including any definitions herein, shall prevail.

[0223] Equal portions While specific embodiments of the present invention have been described, the above specification is illustrative and not limiting. Many variations of the present invention will become apparent to those skilled in the art by examining this specification and the following claims. The full scope of the present invention should be determined by referring to the claims, together with the full scope of equivalents, and the specification, together with such variations.

Claims

1. A lipidoid composition comprising a plurality of lipidoids and an adjuvant, an antigen or a nucleic acid.

2. The lipidoid composition of claim 1 , wherein each lipidoid independently comprises an amine head and a hydrophobic tail.

3. 3. The lipidoid composition of claim 2, wherein each amine head group independently comprises an alkylamine, an arylamine, a heteroarylamine, or a heterocyclylamine.

4. Each amine head may independently be 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, and each dashed line represents a connection to a hydrophobic tail. (i) each amine head independently comprises: 【Chemistry 2】 or a pharma- ceutically acceptable salt thereof, wherein each dashed line represents a connection to a hydrophobic tail; or (ii) each amine head independently represents 【Chemistry 3】 or a pharma- ceutically acceptable salt thereof, wherein the dashed line represents the connection to the hydrophobic tail.

6. Each hydrophobic tail can independently be selected from the group consisting of C 1 ~C 30 Alkyl chain, C 1 ~C 30 Alkyl acyl chain, C 1 ~C 30 Alkyl ester chain, or C 1 ~C 30 A lipidoid composition according to any one of claims 2 to 5, comprising an alkylamide chain.

7. C 1 ~C 30 The lipidoid composition of claim 6 , wherein at least one carbon atom of the alkyl is replaced with a heteroatom.

8. 8. The lipidoid composition of claim 7, wherein each heteroatom is independently selected from the group consisting of N, O, S, and Se.

9. 9. The lipidoid composition of any one of claims 2 to 8, wherein each hydrophobic tail is independently substituted with alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide.

10. The lipidoid composition of any one of claims 2 to 9, wherein each hydrophobic tail is independently substituted with halo.

11. Each hydrophobic tail has the formula: 【Chemistry 4】 comprising or consisting essentially of During the ceremony, The dashed line represents the bond to the amine headgroup. m1 is an integer from 4 to 30; m2 is an integer from 4 to 30; m3 is an integer from 4 to 30; m4 is an integer from 4 to 30; m5 is an integer from 4 to 30; m6 is an integer from 4 to 30; n1 is an integer from 4 to 30; n2 is an integer from 4 to 30; n3 is an integer from 4 to 30; n4 is an integer from 4 to 30; n5 is an integer from 4 to 30; n6 is an integer from 4 to 30; n7 is an integer from 4 to 30; The lipidoid composition according to any one of claims 2 to 5, wherein n8 is an integer from 4 to 30.

12. Each hydrophobic tail is 【Chemistry 5】 6. The lipidoid composition of any one of claims 2 to 5, comprising or consisting essentially of: (i) each hydrophobic tail comprises: 【Chemistry 6】 wherein the dashed line represents the connection to the amine head; or (ii) each hydrophobic tail comprises: 【Chemistry 7】 6. The lipidoid composition of any one of claims 2 to 5, comprising or consisting essentially of:

14. The lipidoid composition of claim 13 , wherein the alkyl chain is substituted with halo.

15. The lipidoid composition of claim 1, wherein the adjuvant, antigen or nucleic acid is encapsulated within the lipidoid composition.

16. The lipidoid composition according to any one of claims 1 to 15, wherein the plurality of lipidoids form a bilayer.

17. The lipidoid composition of claim 16, wherein the adjuvant, antigen or nucleic acid is encapsulated within the bilayer.

18. A lipidoid composition according to any one of claims 1 to 17, comprising an adjuvant, said adjuvant being an immunomodulator or a stimulator of the immune system. (i) the adjuvant is a stimulator of the immune system, the stimulator of the immune system being an immune enhancer or an immune inhibitor; or (ii) The lipidoid composition of claim 18, wherein the adjuvant is an immunomodulatory agent, the immunomodulatory agent being stimulator of one or more immune-related genes (STING).

20. 20. The lipidoid composition of claim 19, wherein the adjuvant is stimulator of interferon genes (STING).

21. The lipidoid composition of claim 19 or 20, wherein the STING is a STING agonist.

22. The lipidoid composition of claim 21 , wherein the STING agonist is a cyclic dinucleotide.

23. The lipidoid composition of claim 22, wherein the STING agonist is cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).

24. A lipidoid composition according to any one of claims 1 to 17, comprising an antigen, said antigen being a vaccine.

25. (i) the antigen is a protein, or 25. The lipidoid composition of claim 24, wherein (ii) the antigen is an attenuated virus.

26. A lipidoid composition according to any one of claims 1 to 17, comprising a nucleic acid, said nucleic acid being DNA or RNA.

27. The lipidoid composition of claim 26, wherein the nucleic acid is mRNA.

28. The lipidoid composition of claim 27, wherein when the mRNA comes into contact with a cell, the mRNA induces the synthesis of a protein belonging to a cancer cell.

29. 29. The lipidoid composition of claim 28, wherein the cancer cell is a bladder cancer cell, a breast cancer cell, a brain cancer cell, a bone cancer cell, a cervical cancer cell, a colorectal cancer cell, a head cancer cell, a neck cancer cell, a kidney cancer cell, a liver cancer cell, a lung cancer cell, a lymphoma cell, a mesothelioma cell, a myeloma cell, a prostate cancer cell, a skin cancer cell, a thyroid cancer cell, an ovarian cancer cell, or an endometrial cancer cell.

30. The lipidoid composition of any one of claims 1 to 29, further comprising a chemotherapeutic agent.

31. The lipidoid composition of claim 30, wherein the chemotherapeutic agent is cytotoxic.

32. 32. The lipidoid composition of claim 30 or 31, wherein the chemotherapeutic agent is an alkylating agent, antimetabolite, anti-microtubule agent, antitumor antibiotic, or topoisomerase inhibitor, antimitotic agent, or corticosteroid.

33. The chemotherapeutic agent may be selected from the group consisting of altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, temozolomide, thiotepa, trabectedin, carmustine, lomustine, streptozocin, azacitidine, 5-fluorouracil (5-Fu), 6-mercaptopurine (6-MP), capecitabine, cladribine, clofarabine, cytarabine (Ara-C), decitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, trifluridine, tipiracil, daunorubicin, doxorubicin, daun ...

33. The lipidoid composition of any one of claims 30 to 32, which is xorubicin, doxorubicin liposome, epirubicin, idarubicin, valrubicin, bleomycin, dactinomycin, mitomycin-C, mitoxantrone, irinotecan, irinotecan liposome, topotecan, etoposide, mitoxantrone, teniposide, cabazitaxel, docetaxel, nab-paclitaxel, paclitaxel, vinblastine, vincristine, vincristine liposome, vinorelbine, prednisone, methylprednisolone, dexamethasone, retinoic acid, arsenic trioxide, asparaginase, eribulin, hydroxyurea, ixabepilone, mitotane, omacetaxine, pegaspargase, procarbazine, romidepsin, or vorinostat.

34. The lipidoid composition according to any one of claims 30 to 33, wherein the chemotherapeutic agent is doxorubicin.

35. The lipidoid composition of claim 27, wherein the mRNA induces the synthesis of a protein belonging to a virus when the mRNA comes into contact with a cell.

36. 36. The lipidoid composition of claim 35, wherein the virus is Hepatitis C virus, Norovirus, Junin virus, Dengue virus, Coronavirus, Human Immunodeficiency Virus, Herpes Simplex Virus, Avian Influenza Virus, Chickenpox Virus, Herpes Labialis Virus, Cold Sore Virus, Glandular Fever Virus, Influenza Virus, Measles Virus, Mumps Virus, Pharyngitis Virus, Pneumonia Virus, Rubella Virus, Severe Acute Respiratory Syndrome Virus, and Lower or Upper Respiratory Tract Infection Virus.

37. The lipidoid composition of claim 36, wherein the virus is a coronavirus, and the coronavirus is SARS-CoV-2.

38. 38. The lipidoid composition of claim 37, wherein the SARS-CoV-2 is an alpha, beta, gamma, delta, or omicron strain of SARS-CoV-2.

39. The lipidoid composition of claim 37 or 38, wherein the mRNA induces synthesis of SARS-CoV-2 spike protein when the mRNA contacts a cell.

40. 28. The lipidoid composition of claim 27, wherein the mRNA has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence of SEQ ID NO: 10 or 11.

41. The lipidoid composition of claim 27, wherein the mRNA has a sequence according to SEQ ID NO: 10 or 11.

42. A pharmaceutical composition comprising the lipidoid composition of any one of claims 1 to 41 and a pharma- ceutically acceptable excipient.

43. 43. The pharmaceutical composition of claim 42, formulated for delivery to immune cells of a subject.

44. and / or 44. The pharmaceutical composition of claim 42 or 43, further comprising an immunomodulatory agent.

45. A composition for treating or preventing a disease or disorder in a subject in need thereof, comprising a lipidoid composition according to any one of claims 1 to 41.

46. A composition for treating or preventing cancer in a subject in need thereof, comprising a lipidoid composition according to any one of claims 1 to 34.

47. 47. The composition of claim 46, used in combination with a chemotherapeutic agent.

48. 48. The composition of claim 47, wherein the chemotherapeutic agent is cytotoxic.

49. 49. The composition of claim 47 or 48, wherein the chemotherapeutic agent is an alkylating agent, antimetabolite, anti-microtubule agent, antitumor antibiotic, or topoisomerase inhibitor, mitotic inhibitor, or corticosteroid.

50. The chemotherapeutic agents include altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, temozolomide, thiotepa, trabectedin, carmustine, lomustine, streptozocin, azacitidine, 5-fluorouracil (5-Fu), 6-mercaptopurine (6-MP), capecitabine, cladribine, clofarabine, cytarabine (Ara-C), decitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, trifluridine, tipiracil, dacarbazine ...

50. The composition of claim 49, which is unorubicin, doxorubicin, doxorubicin liposome, epirubicin, idarubicin, valrubicin, bleomycin, dactinomycin, mitomycin-C, mitoxantrone, irinotecan, irinotecan liposome, topotecan, etoposide, mitoxantrone, teniposide, cabazitaxel, docetaxel, nab-paclitaxel, paclitaxel, vinblastine, vincristine, vincristine liposome, vinorelbine, prednisone, methylprednisolone, dexamethasone, retinoic acid, arsenic trioxide, asparaginase, eribulin, hydroxyurea, ixabepilone, mitotane, omacetaxine, pegaspargase, procarbazine, romidepsin, or vorinostat.

51. 51. The composition of claim 50, wherein the chemotherapeutic agent is doxorubicin.

52. The composition of any one of claims 47 to 51, which is administered intratumorally.

53. 53. The composition of any one of claims 47 to 52, which is administered about 6 to 48 hours after the chemotherapeutic agent.

54. The composition of any one of claims 46 to 53, wherein the cancer is a solid tumor.

55. 54. The composition of any one of claims 46 to 53, wherein the cancer is bladder cancer, breast cancer, brain cancer, bone cancer, cervical cancer, colorectal cancer, head cancer, neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, mesothelioma, myeloma, prostate cancer, skin cancer, thyroid cancer, ovarian cancer, or endometrial cancer.

56. The composition of any one of claims 46 to 55, which induces an anti-cancer immune response in a subject.

57. A composition for treating or preventing a viral infection in a subject in need thereof, comprising a lipidoid composition according to any one of claims 1 to 27 and 35 to 41.

58. 58. The composition of claim 57, wherein the viral infection is Hepatitis C, Norovirus, Junin, Dengue virus, Coronavirus, Human Immunodeficiency Virus, Herpes Simplex, Avian Influenza, Chickenpox, Herpes Labialis, Common Cold, Glandular Fever, Influenza, Measles, Mumps, Pharyngitis, Pneumonia, Rubella, Severe Acute Respiratory Syndrome, and lower or upper respiratory tract infections (e.g., Respiratory Syncytial Virus).

59. The composition of claim 58, wherein the viral infection is a coronavirus infection, and the coronavirus is SARS-CoV-2.

60. 60. The composition of claim 59, wherein the SARS-CoV-2 is an alpha, beta, gamma, delta, or omicron strain of SARS-CoV-2.

61. The composition of any one of claims 57 to 60, which induces an anti-viral immune response in a subject.

62. A kit comprising a chemotherapeutic agent and a lipidoid composition according to any one of claims 1 to 34.

63. 63. The kit of claim 62, wherein the chemotherapeutic agent is cytotoxic.

64. 64. The kit of claim 62 or 63, wherein the chemotherapeutic agent is an alkylating agent, antimetabolite, anti-microtubule agent, antitumor antibiotic, or topoisomerase inhibitor, antimitotic agent, or corticosteroid.

65. The chemotherapeutic agent may be altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, temozolomide, thiotepa, trabectedin, carmustine, lomustine, streptozocin, azacitidine, 5-fluorouracil (5-Fu), 6-mercaptopurine (6-MP), capecitabine, cladribine, clofarabine, cytarabine (Ara-C), decitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, trifluridine, tipiracil, daunorubicin, 65. The kit of any one of claims 62 to 64, wherein the therapeutic agent is selected from the group consisting of ribavirin, doxorubicin, doxorubicin liposome, epirubicin, idarubicin, valrubicin, bleomycin, dactinomycin, mitomycin-C, mitoxantrone, irinotecan, irinotecan liposome, topotecan, etoposide, mitoxantrone, teniposide, cabazitaxel, docetaxel, nab-paclitaxel, paclitaxel, vinblastine, vincristine, vincristine liposome, vinorelbine, prednisone, methylprednisolone, dexamethasone, retinoic acid, arsenic trioxide, asparaginase, eribulin, hydroxyurea, ixabepilone, mitotane, omacetaxine, pegaspargase, procarbazine, romidepsin, and vorinostat.

66. 66. The kit of claim 65, wherein the chemotherapeutic agent is doxorubicin.